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Abstract
Physiologically Based Kinetic (PBK) models predict the internal concentration of chemicals in different
organs after exposure. They are developed and applied to reduce animal studies for risk assessment.
Goats are commonly kept for both recreation and consumption, making it a relevant species for assessing
the risk of chemical exposures, e.g. due to medicine treatment or environmental pollution. In this study,
an existing generic PBK model, previously developed by Radboud University, was adjusted to accurately
fit the goat physiology. It was then implemented and validated. The necessary model parameters were
obtained by systematic literature review. The adjusted model was implemented into the software program
R. In the early exposure phases, the new goat model accurately predicts internal tissue concentrations.
This is not the case for all biological processes or in later exposure phases. The main reason for this is
the lack of available physiological data for goats, such as body weight of organs and blood flow fractions.
For the missing parameters, values for sheep were used. In addition, insufficient suitable studies were
available for the validation of the goat-adjusted model. Here, values for toxicokinetic parameters, such
as the absorption rate constant and clearance rates, were unavailable. Allometric scaling was used to
extrapolate values for these parameters, using data from sheep and cattle. More in vitro and in vivo
studies are necessary to reduce the knowledge gaps to allow the reliable application of the generic PBK
model for goats.
Samenvatting
Fysiologisch gebaseerde kinetische modellen voorspellen de interne concentraties van (chemische) stoffen
in verschillende organen na blootstelling. Ze worden ontwikkeld en toegepast om het benodigde aantal
dierproeven voor risicobeoordeling te reduceren. Geiten worden veel gehouden voor zowel recreatieve
als consumptiedoeleinden. Dit maakt het een relevante soort voor risicobeoordeling van bijvoorbeeld
milieuvervuiling of medicijngebruik. In deze studie wordt een bestaand generiek model (eerder ontwikkeld
door de Radboud Universiteit) aangepast om de fysiologie van de geit nauwkeurig te beschrijven. Het
model is daarna gëımplementeerd en gevalideerd. De nodige model-
parameters zijn gevonden met behulp van literatuurstudie. Het aangepaste model is gëımplementeerd
in de software R. In vroege blootstellingsfases, voorspelt het nieuwe geitmodel de interne concentraties
nauwkeurig. Dit is niet het geval voor alle biologische processen en tijdens latere blootstellingsfases.
De belangrijkste reden hiervoor is het gebrek aan beschikbare fysiologische data, zoals orgaangewichten
en bloedstromen, voor geiten. Voor de missende parameters zijn waardes van het schaap gebruikt.
Ook waren onvoldoende geschikte studies beschikbaar voor de validatie van het aangepaste model.
In de beschikbare studies misten de waardes voor de benodigde toxicokinetische parameters, zoals de
absorptiecoefficient. Voor het verkrijgen van waardes voor deze parameters is allometrisch schaling, met
behulp van data van schaap en rundvee, gebruikt. Meer in vitro en in vivo studies zijn nodig om de
kennislacunes te verminderen om dit generieke model toepasbaar te maken voor de geit.
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Chapter 1
Goal and Problem Description
1.1 Risk Assessment
There are many chemicals in the environment. Some of these chemicals are natural, while others are
synthetically made by industries. These chemicals, especially those that are synthetically made, can
cause harm to the environment as well as human health. Because the effects of chemicals on human,
animal and environmental health are often unclear, risk assessments can be performed to determine this
risk.
Due to the risks associated with chemicals, legislation has been developed and is
continuously applied by multiple organizations. The European Food Safety Authority (EFSA) is such
an organization (EFSA, 2016). Methods for risk assessment have been developed and are harmonized
in order to make the process more transparent, results more comparable and communication about the
risks possible (WHO, 2009). This must lead to implementable legislation, policy and regulations.
1.2 PBK Models and Risk Assessment
The World Health Organization (WHO) defines Physiologically Based Pharmacokinetic (PBPK) models
as “quantitative descriptions of the absorption, distribution, metabolism and excretion (ADME) of
chemicals in biota based on interrelationships among key physiological, biochemical and physicochemical
determinants of these processes” (WHO, 2010)1.
PBK models are one-compartmental or multi-compartmental. In a one-compartmental PBK model, the
compartment represents a whole organism. For multi-compartmental PBK models, each compartment is
based on organs and tissue groups, with physiological characteristics often based on experimental data
(Chiu et al., 2007; Clewell & Clewell, 2008). As is visible in Figure 1.1, the PBK model is therefore
shown as a scheme of boxes and arrows (WHO, 2010). Each of these represents a realistic organ or group
of organs or physical process.
PBK models are important tools for chemical risk assessment (Chiu et al., 2007; Clark et al., 2004; Clewell
& Clewell, 2008; WHO, 2010). These models can be used in several ways, which makes them useful for
risk assessments involving human health, such as extrapolations across studies, species, exposure routes
and dose levels (Barton et al., 2007; Chiu et al., 2007; Clark et al., 2004; Clewell & Clewell, 2008; WHO,
2010). These model applications could lead to less animal testing. Therefore the development and use
of PBK models may have a positive influence on animal welfare.
1.3 Problem Statement
In recent years, multiple PBK models have been developed in the field of animal health and veterinary
medicine. These were mostly used for predictions of tissue residues and withdrawal intervals in farm
animals (Lin et al., 2016). While for other species, such as rats, mice, chicken, cows, sheep and swine,
multiple PBK models are available, only one PBK model was found in literature for the goat. This
model was specifically developed for tulathromycin (Leavens et al., 2011).
1Note: the terms PBK, PBPK, PBTK and PBBK are all synonymous (Paini et al., 2019). I have chosen to use
‘Physiologically Based Kinetic (PBK) model’ for this thesis, unless otherwise specified, as this is the most accurate term.
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Figure 1.1: An example of a multi-compartmental PBK model (WHO, 2010)
It is inefficient for risk assessors, such as EFSA, to continuously develop new PBK models for different
species and each chemical. They prefer a generic PBK model that can be used for different species as well
as different chemicals. Therefore, EFSA requested several research institutes to develop generic tools and
methods for PBK modeling (Lautz et al., 2017). This led to the development of a generic PBK model
structure, which is compatible with chicken, cattle, swine and sheep, by Radboud University Nijmegen,
the Netherlands.
Goats are another category of commonly kept farm animals, both for recreation as well as for consumption.
In 2016, the EU held 12.8 million goats for milk and meat production (EU, 2018). Goat-related products
are thus important consumption products in the EU. This makes it a priority to assess the potential
risks of chemicals associated with these products and the welfare of the goats. Therefore, it is desirable
to also develop a generic PBK model for this species.
1.4 Research Objective
The aim of this study is to adapt the existing generic Physiologically Based Kinetic (PBK) modeling
platform for farm animals developed by Radboud University to accurately describe the internal dose, in
blood and/or urine and possibly target organs, of compounds in the goat. The model must be usable for
different chemical compounds.
1.5 Research Questions
The research objective has led to the following main question:
Can the available PBK model structure for farm animals as developed by Lautz et al. (2017) be adapted
and parameterized to result in a PBK model for goats that can be used to accurately describe the internal
dose of compounds in these animals?
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The main question can be divided into the following sub-questions:
1. What does the current generic PBK model of Lautz et al. (2017) look like?
2. What compartments must be included in the PBK model to accurately reflect the physiology of the
goat?
3. What (physiological) processes must be included in the PBK model to accurately reflect the fate of
chemicals in the goat?
4. What information is available on the compartments and (physiological) processes of the goat and how
can this information be used to optimally parameterize the goat model?
5. What data is available for the validation of the PBK model?
6. How does the PBK model perform based on this validation data?
1.6 Research Method
First the existing generic PBK model structure will be described. This model has already been implemented
into the statistical software suit R. After this description, a literature study will be conducted. The
literature study should clarify whether there are differences between goats and other farm animal species
that must be taken into consideration for the PBK model. It should supply the information necessary to
determine which compartments and (physiological) processes must be implemented in the goat-specific
PBK model.
If found necessary, adjustments will be made to the generic PBK model structure by adding the
goat-specific compartments and/or (physiological) processes. These changes should make the model
suitable for the goat. The necessary physiological parameters will also be adjusted to make the model
suitable for the goat. Afterwards, another literature study will be conducted in order to find experimental
data which can be used to validate the PBK model for the goat. This data will be specific for certain
chemicals, namely ivermectin, chloramphenicol and moxifloxacin. These compounds were chosen because
of the availability of data on their tissue distribution after oral or intravenous application.
Next, the found information will be put into the adjusted goat PBK model. After this, the model is
run in R. The results produced by the adjusted PBK model will be compared to the experimental data
and conclusions will be drawn from these results. Figure 1.2 shows a flowchart summarizing the research
approach.
1.7 Reader’s guide
Figure 1.2 shows the reader’s guide for this thesis. Chapter 2 describes the current generic PBK model,
as made by Lautz et al. (2017). It shows the compartments (Section 2.1) and mathematical equations to
show relations between the compartments in Section 2.2. In Chapter 3 the current model is adapted to
become goat-specific. This is divided in the necessary compartments (Section 3.1) and the general model
parameters needed for the goat-adjusted model (Section 3.2). Then the parameters are implemented into
the model, which is validated in Chapter 4. Section 4.1 defines the selection process of the validation
studies, after which the model is run and Sections 4.2 through 4.4 give specific explanations for the
three chosen studies and their results. Chapter 5 discusses the found results, draws conclusions and
gives recommendations. The model code is added in Appendix A. The raw results of the model runs for
validations are available in Appendix B.
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Figure 1.2: Flowchart summarizing the research approach.
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Chapter 2
Description of Current PBK Model
The PBK model developed by Lautz et al. (2017) is a generic PBK model that can be used for cattle,
sheep, swine and chicken. It consists of multiple compartments that interact with each other through
different (physiological) processes. Figure 2.1 shows an example when this PBK model is applied to the
swine. This chapter describes the current generic PBK model and supplies the mathematical equations
showing the interactions between the different compartments and processes.
Figure 2.1: Multi-compartmental generic PBK model for the following species: cattle, sheep, swine and
chicken (Lautz et al., 2017).
2.1 Compartments
What happens to a substance when it enters the body, depends on the characteristics of the involved
species as well as those of the substance. How a PBK model deals with these characteristics depends on
whether it is a one-compartmental or multi-compartmental model. The current generic PBK model, as
developed by Lautz et al. (2017), is a multi-compartmental PBK model. This means that the body is
not seen as a whole, as is the case for a one-compartmental model, but as having multiple compartments,
such as heart, liver, lungs and blood.
The body consists of multiple organs, such as the heart, lungs, liver and intestine. Several of these
organs are species-specific. For example, ruminant species have multiple organs which together make
up the stomach, while for other species the stomach is one organ. Each of the organs is a homogeneous
compartment in the multi-compartmental PBK model. Other compartments also play a role in processing
chemicals in the body. Blood for example is a compartment that influences the distribution of chemicals
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throughout the body. Some chemicals may also be stored in fat or muscle tissue. These compartments
are therefore also included in the multi-compartmental PBK model.





















 Rest of Body
2.2 (Physiological) Processes
The different compartments interact with each other and the chemical through different (physiological)
processes, the so-called ADME processes: Absorption, Distribution,
Metabolism and Excretion. The toxicokinetic data for chemicals going through these processes is key
information needed to create a PBK model (EFSA, 2014). The current generic PBK model is therefore
also based on the ADME processes. The processes must be translated into mathematical equations to
be integrated into the PBK model. Before the mathematical equations will be given, a short explanation
is supplied for each of the ADME processes.
Absorption
The first of the processes is absorption. The World Health Organization (WHO) has defined absorption
as: ’the process by which a substance is transferred from the site of administration into the circulation.
For chemicals in food, absorption usually refers to passage across the gut wall into the circulation,
although for some chemicals, uptake may be only as far as the epithelium of the gastrointestinal
tract’ (WHO, 2010). In the field of food safety, the most common route of exposure to consider is
oral ingestion. After ingestion, the compound travels over the intestinal wall into the blood of the
portal vein, which transports it into the liver and where it becomes bioavailable when entering the
systemic circulation (EFSA, 2014). The fraction of the drug that reaches systemic circulation is called
oral bioavailability. Oral bioavailability depends on multiple factors, including solubility, dissolution,
permeability, transporter affinity, metabolism in the lumen, intestine and/or liver (Bueters et al., 2013).
Distribution
When a compound is in the systemic circulation, it can be distributed throughout the body to the
different compartments (EFSA, 2014). The amount of compound that can be received and can remain in
the organ or tissue, differs for each organ or tissue. The distribution of a compound between the blood
and the tissue can continue taking place until a steady-state has been found. The distribution rate for
compounds depends on the following factors:
 vascular permeability;
 regional blood flow;
 cardiac output;
 perfusion rate of the tissues;
 tissue and plasma protein binding ability; and
7
 lipophilicity (EFSA, 2014).
Of the above-mentioned factors, the ability of a compound to bind to protein is most important. This is
a quality that differs greatly between compounds and determines how much of the compound is free to
be distributed into the tissues and organs, and with that influences the toxicokinetics in general (EFSA,
2014). The ability of the compound to bind to proteins therefore determines the tissue:blood partitioning
coefficient of the compound (Yoon et al., 2012).
Metabolism
The next ADME process is metabolism. Metabolism is the breakdown of a compound within an organism.
The metabolism of chemicals can occur in any tissue of the body (Chiu et al., 2007; EFSA, 2014). The
two most important sites of the body where metabolism takes place are the intestinal lumen and the
liver. In addition to metabolism by these two compartments, metabolism taking place in the lungs is
also included in the current generic PBK model.
Distinction is made between phase I and phase II metabolism. During phase I, a hydrophobic compound
is transformed into a polar substance. In phase II, the polar substance is transformed into a hydrophilic
substance, the conjugate (Yoon et al., 2012). In general, this conjugate is excreted with the bile. However,
it is also possible for the conjugated compound to be de-conjugated.
When enterohepatic circulation takes place, the chemical compound enters the liver, is metabolized and
is excreted into the intestinal lumen. Here, bacteria can convert the metabolized compound back into
the original parent compound. This newly created parent compound is then again absorbed into the
blood of the portal vein and distributed to the liver to be metabolized. Therefore, for some chemicals,
part of the compound is recycled, influencing the overall metabolism rate.
Excretion
The last of the ADME processes is excretion. Different organs are involved in the excretion process, such
as the kidneys, liver, lungs and skin (EFSA, 2014). In the current model, excretion through the skin has
not been taken into consideration. For food safety, excretion through the reproductive system must also
be taken into consideration (Lautz et al., 2017). In the current PBK model, routes for livestock include
excretion via milk for mammals (cow and sheep) and via eggs for the chicken.
It is complicated to determine the renal excretion, due to the tubular transport structures of the kidney.
Besides the difficult structure, there are also multiple transporter proteins involved, complicating the
situation further. In the current PBK model, default assumptions are made about the excretion of
compounds, but more research into the interaction between transporter proteins and renal excretion
might lead to a better understanding of renal clearance as derived from the glomerular filtration rate
(EFSA, 2014; Lautz et al., 2017).
In the following sections, the (physiological) processes are described for each of the compartments, as
they are implemented in the generic PBK model by Lautz et al. (2017). For each compartment, the
necessary ADME processes are described and translated into mathematical equations. There are several
general model equations, which are followed by the organ specific equations.
2.2.1 General Model Equations
In general, the change in the amount of a chemical in an organ is determined by the difference between
the incoming and outgoing amounts of the compound. This is dependent on the amount of the chemical
that is metabolized, accumulated, excreted and transported to the venous blood (Lautz et al., 2017).
The arterial blood brings the compound to the organ, while it flows away from the organ with the venous
blood. Equation 2.1 describes the change in the amount of chemical over time in a general equation.
This general equation is applicable to all organs, except if otherwise specified in Section 2.2.2.
dM tissue
dt




dt = change in the amount of chemical in a compartment (µmol/h);
Qt = blood flow through the tissue (L/h);
Cart = arterial blood chemical concentration (µmol/L);
Cven = venous blood chemical concentration (µmol/L).
Lautz et al. (2017) assume a blood flow-limited model. This means that the concentration of the
compound in the tissue is equal to the concentration of the compound in the blood leaving the tissue.
Therefore, the concentration of the compound in the venous blood (Cven) can be substituted by the
tissue concentration (Ct) and the tissue/blood partitioning coefficient (P t), leading to Equation 2.2.
dM tissue
dt





Ct = tissue chemical concentration (µmol/kg);
P t = tissue/blood partitioning coefficient (-).
Entry of Compounds into the Body
In the current PBK model, chemicals enter the body either through feed or through intravenous injection
(IV). Exposure through inhalation, as well as dermal exposure, is not implemented in this model. The
route of exposure determines into which of the compartments (see Section 2.1) the chemical is released
and what happens to the chemical after it has entered the body. Equation 2.3 shows the input of the




= Ebolus[i] ∗Qbolus + Econt[i] ∗Qingest (2.3)
where:
dM feed
dt = intake rate of the compound through feed (mg/min);
Ebolus[i] = administered dosage for a bolus regime (mg);
Qbolus = exposure duration (min
-1);
Econt[i] = administered dosage for a continuous regime (mg/kg feed);
Qingest = ingestation rate (kg feed/min).
The second route of exposure is via injection. Equation 2.4 shows the mathematical equation describing
the input via an IV. Unlike the input via food, the input via injection is always following a bolus regime.
Therefore, there is no term describing a continuous regime in this equation.
dM iv
dt
= Eiv[i] ∗Qiv (2.4)
where:
dM iv
dt = intake rate of the compound administered through an IV (mg/h);
Eiv[i] = exposure dose administered (mg);
Qiv = amount of times administered (h
-1).
2.2.2 Compartment Specific Equations
In this section, the mathematical equations are given for each specific compartment. For each of the
compartments, the role of the ADME processes is described.
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Arterial Blood
The first compartment is the arterial blood. The arterial blood flows away from the heart and is therefore
important in the distribution of compounds. The concentration of the compound in the arterial blood
(Cart) is calculated by dividing the mass of the compound in the arterial blood (Mart) by the volume of
the arterial blood (V art), as is shown in Equation 2.5. The assumption is made that there is no difference







Cart = concentration of compound in arterial blood entering the organs (µmol/L);
Mart = mass of the compound in the arterial blood (µmol);
V art = volume of the arterial blood.
Venous Blood
Another important compartment for distribution is the venous blood. The venous blood flows from the
organs to the heart. The model assumes that all venous blood, which leaves the tissues and/or organs, is
mixed. Equation 2.6 takes this assumption into consideration and shows the total mass of the compound












Mven = total mass of compound in venous blood (µmol);
Qt = blood flow from the tissues to venous blood (L/h);
Ct = concentration of compound in tissue (µmol/L);
P t = tissue:blood partitioning coefficient for compound(-);
Qgut = blood flow to the gut (L/h);
Qliver = blood flow to the liver (L/h);
C liver = concentration of the compound in the liver (µmol/L tissue);
P liver = liver:blood partitioning coefficient for compound (-).
The concentration in the venous blood can then be calculated by dividing the mass flow of the compound
by the total cardiac output (see Equation 2.7). For the venous blood, the same assumption is made as is
the case for the arterial blood. Therefore, there is no distinction made between the venous blood leaving






Cven = concentration of compound in venous blood leaving the organs (µmol/L);
Mven = total mass of compound in venous blood (µmol);
Qtot = cardiac output (L/h).
Gastrointestinal Tract
The gastrointestinal tract is divided into two sub-compartments: the gut lumen and the gut tissue.
Each sub-compartment plays a separate role in processing compounds. The gut lumen plays a role in
enterohepatic circulation and the metabolism of compounds, while the gut tissue is important for the
distribution of compounds from the gut to the liver. Therefore, individual mathematical equations are
developed for each of the two sub-compartments.
10
Gut Lumen
The first sub-compartment of the gastrointestinal tract is the gut lumen. The change in the amount of
compound in the gut lumen (
dM lumen
dt ) is dependent on multiple processes. This is shown in Equation
2.8. The amount of compound entering the gut lumen is determined by the amount of food flowing into
the gut lumen from the stomach (Qfood) and the concentration of the compound in this food (C intake).
The conjugated compound also enters the gut lumen with the bile, of which a fraction can be transformed
back into the parent compound for enterohepatic circulation (fbact).
The amount of compound that leaves the gut lumen is a combination of the amount taken up by the
gut tissue (M lumen ∗ kabs) and the amount of compound excreted with the feces (M lumen ∗ kgastric). In




=Qfood ∗ C intake + fbact ∗ fbile ∗ (Clhepatic ∗ C liver)




dt = change in amount of compound in the gut lumen (µmol/h);
Qfood = food flow from stomach to intestine (L/h);
C intake = concentration of compound in food flow (µmol/L);
fbact = fraction of conjugate that is transformed back into parent compound in the gut
lumen (-);
fbile = fraction of conjugate that flows into bile (-);
Clhepatic = hepatic clearance rate (L/h);
C liver = concentration of compound in liver (µmol/L);
M lumen = amount of compound in the gastrointestinal lumen (µmol);
kabs = absorption rate of compound into gut tissue (h
-1);
kgastric = gastric emptying rate (h
-1).
Gut Tissue
The second sub-compartment of the gastrointestinal tract is the gut tissue. The change in amount of the
compound in the gut tissue (
dMgut
dt ) is determined by the general equation (Equation 2.2) applied to the
gut tissue and the addition of the amount of compound absorbed from the gut lumen (M lumen ∗ kabs).
Equation 2.9 shows this change in compound in the gut tissue.
dMgut
dt
= Qgut ∗ (Cart −
Cgut
P gut
) +M lumen ∗ kabs (2.9)
where:
dMgut
dt = change in amount of compound in the gut tissue (µmol/h);
Qgut = blood flow to the gut (L/h);
Cart = concentration of compound in arterial blood flowing to the gut (µmol/L);
Cgut = concentration of compound in gut (µmol/L);
P gut = gut:blood partitioning coefficient for compound (-);
M lumen = amount of compound in the gastrointestinal lumen (µmol);
kabs = absorption rate of compound into gut tissue (h
-1).
Liver
The next compartment in the current PBK model is the liver. The liver is considered the most important
metabolizing organ. The blood flow around the liver consists of the portal vein (Qgut), flowing from the
gut to the liver, and the hepatic artery (Qliver). The compound often gets excreted out of the liver in the
form of conjugates, via the bile into the gut lumen (fbile in Equation 2.9). The change in the amount of
compound in the liver over time (
dM liver
dt ) is shown in Equation 2.10.
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Part of the conjugates that are excreted out of the liver with the bile, may be subject to enterohepatic
circulation. The process of enterohepatic circulation is described in Section 2.2. The conjugates are
metabolized back into the original parent compound and are recycled back to the liver through the
portal vein. This is shown as fbact in Equation 2.8.
dM liver
dt















dt = change in the amount of compound in the liver (µmol/h);
Qliver = blood flow to the liver (L/h);
Cart = concentration of the compound in the arterial blood flowing to the liver (µmol/L);
C liver = concentration of the compound in the liver (µmol/L);
P liver = liver:blood partitioning coefficient for compound (-);
Clhepatic = hepatic clearance rate (L/h);
Qgut = blood flow from the gut tissue (L/h);
Cgut = concentration of the compound in the gut tissue (µmol/L);
P gut = gut tissue:blood partitioning coefficient for the compound (-).
Kidney
The kidney excretes compound from the body. The change in the amount of compound in the kidney
(
dMkidney
dt ) is therefore shown as the general mass balance, combined with a term for excretion (Ckidney ∗
Clrenal). This leads to Equation 2.11.
dMkidney
dt
= Qkidney ∗ (Cart −
Ckidney
P kidney
)− (Ckidney ∗ Clrenal) (2.11)
where:
dMkidney
dt = change in amount of compound in the kidney (µmol/h);
Qkidney = blood flow to the kidney (L/h);
Cart = concentration of the compound in the arterial blood to the kidney (µmol/L);
Ckidney = concentration of the compound in the kidney (µmol/L);
P kidney = kidney:blood partitioning coefficient of the compound (-);
Clrenal = renal clearance rate (L/h).
Lungs
In the current generic PBK model, the lungs are sources of metabolism and excretion of compounds.
Exposure through inhalation is not taken into account in the model. In Equation 2.12, the pulmonary
blood flow is represented. This is in contrast to the bronchial blood flow, that is part of the remainder of
the body and can be determined with Equation 2.1. The pulmonary blood flow consists of the pulmonary
artery, that flows from the heart to the lungs and is low in oxygen, and the pulmonary vein, that flows
from the lungs to the heart and is rich in oxygen. From the heart the oxygen-rich blood is then distributed
to the remainder of the body.
dM lung
dt
=Qtot ∗ (C lven − C lart)
− Qexhale ∗ P air





dt = change in amount of compound in the lung (µmol/h);
Qtot = cardiac output (L/h);
C lven = concentration of compound in venous blood entering lungs (µmol/L);
C lart = concentration of compound in arterial blood leaving lungs (µmol/L);
Qexhale = mammalian ventilation rate (L/h);
P air = lung:blood partitioning coefficient of the compound (-);
Mammary Gland and Lumped Reproductive Organs
Another route of excretion is through the mammary gland and lumped reproductive organs. In the
current model, the mammary gland (and milk production) are taken into consideration for cattle and
sheep. For chicken, excretion through the production of eggs was included in the model.
Mammary Gland
Mammals produce milk, which can be a route of excretion for compounds. As this milk is used in
many (consumer) products, it is important for food safety to have knowledge on this route of exposure.
Equation 2.13 shows that the change in the amount of compound in the mammary gland (
dMmgland
dt ) can
be described by the general mass balance, in addition to a factor describing the excretion (Qmilk∗Cmgland).
dMmgland
dt
= Qmgland ∗ (Cart −
Cmgland
Pmgland
)− (Qmilk ∗ Cmgland) (2.13)
where:
dMmgland
dt = change in amount of compound in the mammary gland (µmol/h);
Qmgland = blood flow rate to mammary gland (L/h);
Cart = concentration of compound in arterial blood to mammary gland (µmol/L);
Cmgland = concentration of compound in mammary gland (µmol/L);
Pmgland = mammary gland:blood partitioning coefficient for compound (-);
Qmilk = flow rate of milk (L/h).
Eggs
Chickens do not produce milk, but they do produce eggs. These eggs are also used for consumption
and therefore are also important to be taken into consideration for food safety. The mass balance for
the production of eggs is similar to the mass balance for milk production. Equation 2.14 shows that
to determine the change in the amount of compound in the reproductive system (
dMrep
dt ) the general
mass balance is needed, in addition to a term for the excretion of the compound through eggs (Qegg∗Crep).
dM rep
dt
= Qrep ∗ (Cart −
Crep
P egg
)− (Qegg ∗ Crep) (2.14)
where:
dMrep
dt = change in the amount of compound in the reproductive system (µmol/h);
Qrep = blood flow rate to the reproductive system (L/h);
Cart = concentration of the compound in the arterial blood flow to reproductive system
(µmol/L);
Crep = concentration of the compound in the reproductive system (µmol/L);
P egg = egg:blood partitioning coefficient for the compound (-);
Qegg = egg production rate (L/h).
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Chapter 3
Goat-specific Adaptation of Current
PBK Model
The current PBK model, as developed by Lautz et al. (2017), can be used for cattle, sheep, swine and
chicken. However, the goal of this thesis is to adjust and parameterize this model, in order for it to
accurately describe the internal dose of different compounds in goats. In this chapter, the goat-specific
physiological parameters and values will be elaborated on and implemented into the model. Necessary
assumptions are also explained in this chapter.
3.1 Goat-Adjusted Model Compartments
In order to adjust the current generic PBK model to fit the goat, there are specific physiological
parameters which must be implemented or excluded from the current model. Literature studies have
shown which compartments, and corresponding physiological parameters, are of importance for the goat.
Like sheep and cattle, goats are a ruminant species, meaning their stomach consists of four compartments.
These four compartments replace the ’stomach’ compartment of the generic model (Section 2.1).
The gizzard and crop were also removed for the goat-adjusted PBK model, as goats do not have these
organs. In the generic model by Lautz et al. (2017), the lumped reproduction organs are only applicable
to chickens. Therefore, the assumption is made that this compartment is not applicable to goats. For the
goat-adjusted PBK model, the following selection of compartments from the current model (see Section
2.1) is needed:















For each of the compartments, multiple physiological parameters must be included in the model. This
can be verified by the previously mentioned equations (see Section 2.2.2). These parameters include the
weight and blood flow fractions of target organs. The values that are implemented in the goat-specific
model, are detailed in Section 3.2.
3.2 Model Values for Implementation
In this section, the values of the physiological parameters, as implemented into the goat-specific PBK
model, are given. These values were derived from multiple literature studies. For several compartments,
14
only one value was found. However, for other parameters, multiple studies were available. To establish
the input distribution, the found data had to be combined. Equation 3.1 shows how data were combined,
using the method developed by Ragas and Huijbregts (1998). In this method, the arithmetic means and
standard deviations are combined, based on the sample size of the respective studies (Lautz et al., 2017;








Gcombined = combined mean of two or more studies x;
Nx = sample size of study x;
Gx = mean of the individual study x;










[(Nx − 1) ∗ SD2x +Nx ∗G2x
− 2 ∗Nx ∗Gx ∗Gcombined +Nx ∗G2combined])
(3.2)
where:
SD2combined = combined squared standard deviation of studies x;
SD2x = squared standard deviation of study x.
3.2.1 Assumptions
Several assumptions were made for the goat-adjusted PBK model. These assumptions are necessary to
have a working model. This section elaborates which assumptions were made and why these specific
choices were made. For the following topics, assumptions were made for the goat-adjusted model:
1. allometric scaling;
2. tissue composition parameters for mammals; and
3. the use of sheep data.
Allometric Scaling
The first subject is the use of allometric scaling in the goat-adjusted PBK model. There are two equations
that describe the allometric relationships. The first being an exponential equation (Equation 3.3). One
can also make a linear equation out of this, after a logarithmic transformation, leading to Equation 3.4
(Lautz et al., 2017).
Y = a ∗W b (3.3)
log Y = log a+ b ∗ logW (3.4)
where:
Y = parameter under study;
a = allometric coefficient (intercept of the linear equation);
W = body weight of the species (kg);
b = allometric exponent (slope of the linear equation).
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In the specific case where the values for Ys and Ws are known for one species, and the weight (Wn) of
the species of interest is known, one can rewrite Equation 3.3 into Equation 3.5:
Y n = (
W s
W n
)1−b ∗ Y s (3.5)
where:
Y n = parameter under study of the species of interest;
W n = body weight of the species of interest (kg);
Y s = experimental value of the parameter under study for another species that is used
as a basis for extrapolation;
W s = body weight of the other species that is used for extrapolation (kg).
Not all compounds qualify for allometric scaling. Lautz et al. (2017) argue that compounds that are
mainly excreted through renal clearance, do qualify for allometric scaling. This is due to the well
documented knowledge on renal physiology for many mammals. However, compounds that are excreted
through hepatic clearance should not be used in allometric scaling, as the hepatic metabolism differs
significantly between species (Lautz et al., 2017). This limits the amount of compounds that can be used
for the validation of the goat-adjusted PBK model. An exception to this, is when it is ensured that at
least 80% of the compound is excreted through renal clearance.
The availability of compounds that were tested on multiple tissues of goats is limited. Therefore, some
toxicokinetic data (available in Table 4.2) was extrapolated from available data of other species using
allometric scaling. For two out of three of the chosen validation studies, the absorption coefficient (kabs),
renal and hepatic clearance rates were extrapolated from data of sheep and cattle. Section 4.1 specifically
shows which parameters were scaled from other species.
Tissue Composition Parameters for Mammals
The model uses tissue composition parameter values for its calculations. It is assumed that these values
are the same for all mammals. This is due to a lack of data showing otherwise. In the goat-adjusted
PBK model, the parameter values are therefore kept the same as in the original PBK model. These
values are given in Table 3.1.
Use of Sheep Data
Besides toxicokinetic data, physiological data of the sheep is also used in the goat-adjusted PBK model.
This model assumes that the physiology of goat and sheep are sufficiently similar and physiological
data of the sheep can therefore be used in the goat-adjusted model when necessary. This is the case
for compartments whose weight is described as a fraction of the body weight, or blood flow which is
described as a fraction of the cardiac output and/or weight of the relevant organ (Table 3.2).
These are the most important assumptions made for this goat-adjusted PBK model. The combination
of these assumptions leads to the model, which will be tested and validated in Chapter 4.
3.2.2 Physiological Parameters
Table 3.1 shows the different tissue composition parameters for the goat. There are four values taken
into consideration, namely the fractions of neutral lipids, polar lipids, proteins and water. As described
in 3.2.1, it is assumed that these values are the same for all mammals. Another parameter is the food
intake rate. For the goat (all sexes) it was assumed the same as for sheep, namely 4.77 kg/day (Lautz
et al., 2017).
Also important is the gastric emptying rate (kgastric), which is set, for all sexes, at 2.083*10
-3 min-1.
This value is based on personal communication with Ad Ragas. It is assumed that the average time
a compound stays in the gastrointestinal tract is 8 hours. This leads to a removal of 300% per day,
meaning kgastric is 3 per day and therefore 2.083*10
-3 per minute.
Using Equations 3.1 and 3.2, the physiological parameter values for the goat-specific PBK model were
calculated. These values are shown in Table 3.2. They are based on literature studies. Several of the
values in Table 3.2 are based on values found for sheep, as explained in Section 3.2.1.
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Table 3.2 shows three values per parameter, one for each sex and a combined (mixed) value. This
distinction was made so users of the model can decide which values best fit their goal. In a test using
both sexes, the combined value can be used, while one can also view the effects of compounds on a
specific sex. The latter can be useful, for example, when determining the effects of a compound on the
milk produced by the female goat.
Three comments about the values in Table 3.2 must be made, namely:
1. the fractions do not add up to 1.00. However, the model normalizes the values of the fractions to
add up to 1.00;
2. the fraction of body weight for the carcass weight was reduced from 0.51, 0.48 and 0.51 for the
male, female and mixed goats respectively, to 0.31 to avoid double calculations of part of the muscle
and fat weight;
3. when data was not available in scientific literature, the assumption was made that the values for
the compartments between sexes are proportional. Meaning the ratio between male and female for
one compartment, is similar to the ratio between male and female for another compartment. This
assumption was used to calculate the missing values (which therefore do not have a reference).
The second point needs more elaboration. In literature found, the carcass weight consists of muscle, bone
and adipose tissue. Muscle and fat are considered separate compartments in the PBK model. Therefore,
the fraction of body weight for the carcass weight needs to be adjusted so muscle and fat are not counted
double in the total body weight. The values were reduced from a fraction of 0.51, 0.48 and 0.51 for
male goats, female goats and mixed goats respectively, to a body weight fraction of 0.31 for the carcass.
Before the reduction, the total of all body weight fractions, was around 1.20. The assumption was made
that the value above 1.00 was for a large part caused by the muscle and adipose tissue being counted
double. Therefore, the adjustment was made, leading to the carcass weight fraction being 0.31.











Fat 0.794 0.000 0.057 0.157
Brain 0.043 0.067 0.080 0.790
Carcass 0.017 0.003 0.193 0.328
Heart 0.047 0.051 0.169 0.734
Intestine 0.045 0.020 0.139 0.792
Kidney 0.013 0.038 0.173 0.776
Liver 0.020 0.049 0.179 0.727
Lung 0.015 0.036 0.125 0.84
Muscle 0.005 0.006 0.172 0.782
Mammary gland 0.042 0.0004 0.035 0.872

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































In this chapter the goat-adjusted PBK model will be validated. First, a selection is made of model
validation sets, after which the model will be run. In Sections 4.2 - 4.4, the results of the model will
then be compared to the experimental data of the validation sets. The used model code is available in
Appendix A and the raw results are available in Appendix B.
4.1 Definition and Selection of Model Validation Sets
The first step in the validation of the goat-adjusted PBK model, is finding literature studies that can
be used for this purpose. An extensive literature search, using Google Scholar, was done in order to
identify suitable case studies. An important criterion for a study to be usable, is that it describes the
tissue distribution of the chemical in the goat, preferably in multiple tissues such as blood, urine, liver,
etc. Only a few studies were available that meet this criterion.
More specifically, only two valid studies were found that describe the tissue distribution of chemicals
within the goat. The first study is about the anti-parasitic medication ivermectin. In this study, a
dosage of 0.2 mg ivermectin per kilogram body weight was given to 9 male goats orally (Lespine et al.,
2005). Ivermectin concentrations were measured in plasma, hair, fat, skin, lung, liver, intestinal mucosa
and abomasal mucosa at 2, 7 and 17 days after exposure.
The second case study is about another antibiotic, namely chloramphenicol. In this study, a gender-mixed
group of 24 goats was intravenously dosed with 25 mg chloramphenicol per kilogram of bodyweight (Etuk
& Onyeyili, 2005b). Chloramphenicol concentrations were measured in liver, skeletal muscle, brain, lungs,
kidney, spleen and bone marrow at 11 points in time starting at 0.08 hours until 240 hours after exposure.
More extensive information on the studies, is given in Sections 4.2 and 4.3.
Neither of the above-mentioned studies gave results on the distribution of the chemical in the milk of
the goat. No case study was found that described both the distribution of the compound in tissues as
well as in milk. As the production of goat milk is also important, the decision was made to add a third
case study, which focuses specifically on the distribution of the compound in the milk. For this, a study
using the antibiotic moxifloxacin was used. In this study, a dosage of 5 mg of moxifloxacin per kilogram
of body weight was given to 6 female goats (Fernandez-Varon et al., 2006). More thorough information
on this study is given in Section 4.4.
The combination of these three case studies, covers the distribution in as many tissues as possible. The
choices also reflect the three possibilities for inclusion of gender in the model, namely male, female and
mixed, as is described in Section 3.2.2. Therefore, these studies include as many different validation
factors as possible, making them a good set to validate the goat-adjust PBK model.
After these case studies were selected, a literature search was performed to find the chemical specific
properties and toxicokinetic parameters of the three compounds. This data is given in Tables 4.1 and 4.2.
Table 4.1 shows the chemical specific properties for the three compounds used for the validation of the
goat-adjusted PBK model. Table 4.2 shows the toxicokinetic parameters and rates of these compounds.
These include the absorption rate into the gut tissue (kabs), the renal and hepatic clearance rates (Clrenal
and Clhepatic respectively).
Several of the values in 4.2 were calculated based on allometric scaling, as is described in Section 3.2.1.
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For ivermectin, kabs was extrapolated from sheep data, using the study by Mestorino et al. (2003). A
body weight for the sheep (Ws in Equation 3.5) of 60 kg was used for the allometric scaling here. Both
the renal and hepatic clearance are based on cattle data from the study by Lanusse et al. (1997). Here
a body weight for the cattle of 210 kg was used. The allometric exponent (b in Equation 3.5) was set at
0.75, based on the study by Duthaler et al. (2020).
For moxifloxacin, kabs and both clearance rates were extrapolated from data of the sheep, using the
study by Goudah (2008). A body weight of 45 kg was used for the sheep. The allometric exponent was
set at 0.8805 based on a study by Huang et al. (2015).













Ivermectin 874.7 4 1.50*10-9 1584.89 Liebig et al. (2010)
Chloramphenicol 323.13 2500 2.27*10-10 13.8 EFSA (2014)
Moxifloxacin 401.4 1146 9.68*10-13 8.91 NCBI, n.d.








Ivermectin Male 0.002 a 1.15*10-5 b 5.66*10-4 b Duthaler et al. (2020),
Lanusse et al. (1997),
Mestorino et al. (2003)
Ivermectin Female 0.0032 c 1.19*10-5 d 5.85*10-4 d Duthaler et al. (2020),
Lanusse et al. (1997),
Mestorino et al. (2003)
Ivermectin Mixed 0.0029 e 1.18*10-5 f 5.76*10-4 f Duthaler et al. (2020),
Lanusse et al. (1997),
Mestorino et al. (2003)
Chloramphenicol Male 0.0889 0.0133 0.00 Etuk & Onyeyili (2005a)
Chloramphenicol Female 0.0889 0.0133 0.00 Etuk & Onyeyili (2005a)
Chloramphenicol Mixed 0.0889 0.0133 0.00 Etuk & Onyeyili (2005a)
Moxifloxacin Male 0.128 g 0.001 g 0.005 g Goudah (2008), Huang et al.
(2015)
Moxifloxacin Female 0.140 h 0.001 h 0.005 h Goudah (2008), Huang et al.
(2015)
Moxifloxacin Mixed 0.132 i 0.001 i 0.005 i Goudah (2008), Huang et al.
(2015)
a Extrapolated from sheep using an extrapolation
factor of 0.75 and a body weight of 60 kg for sheep
and of 19.2 kg for goat.
b Extrapolated from cattle using an extrapolation
factor of 0.75 and a body weight of 210 kg for
cattle and of 19.2 kg for goat.
c Extrapolated from sheep using an extrapolation
factor of 0.75 and a body weight of 60 kg for sheep
and of 16.8 kg for goat.
d Extrapolated from cattle using an extrapolation
factor of 0.75 and a body weight of 210 kg for
cattle and of 16.8 kg for goat.
e Extrapolated from sheep using an extrapolation
factor of 0.75 and a body weight of 60 kg for sheep
and of 17.8 kg for goat.
f Extrapolated from cattle using an extrapolation
factor of 0.75 and a body weight of 210 kg for
cattle and of 17.8 kg for goat.
g Extrapolated from sheep using an extrapolation
factor of 0.8805 and a body weight of 45 kg for
sheep and of 19.2 kg for goat.
h Extrapolated from sheep using an extrapolation
factor of 0.8805 and a body weight of 45 kg for
sheep and of 16.8 kg for goat.
i Extrapolated from sheep using an extrapolation
factor of 0.8805 and a body weight of 45 kg for
sheep and of 17.8 kg for goat.
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4.2 Case Study Ivermectin
4.2.1 Description of Compound
Ivermectin is part of the avermectins, which are macrocyclic lactones. Avermectins are broadly used,
as they are effective against a large number of nematodes, mites and insects. Figure 4.1 shows the
chemical structure of ivermectin. Ivermectin is an anthelmintic, which is commonly used in livestock,
such as goats, sheep and cattle, pets and humans, but also in agriculture to protect fruits and vegetables
(Lespine et al., 2005 & Liebig et al., 2010). It can be given orally or subcutaneously, the latter is the
more efficient route (Campbell, 1985 & Lespine et al., 2005).
Figure 4.1: Chemical structure of ivermectin (Campbell, 1985).
The hydrophobic pharmaceutical compound binds to lipoproteins in the blood This is how ivermectin
distributes itself through the body (Lespine et al., 2005). It is mostly stored in adipose tissue. The
amount of ivermectin that is metabolized by the liver, is very low (Lespine et al, 2005). The compound
is excreted in the same form as it is applied. The main route of excretion of ivermectin is through the
feces, with less than 2% being excreted through the urine (Campbell, 1985; Liebig et al., 2010).
4.2.2 Description of Validation Study
A study performed by Lespine et al. (2005) was used for validation. The goal of this study was to
compare the efficiency of ivermectin in goats, after oral and subcutaneous administration, in the same
supplied dosage. For the validation of the goat-adjusted PBK model, only the data of the orally exposed
goats were used. A total of 24 male French Alpine goats, weighing between 16 and 23 kilograms, were
used for this study. Nine of these goats were given an oral dosage of 0.2 mg ivermectin per kilogram body
weight. Three of the goats were sacrificed at 2, 7 and 17 days, after which blood and tissue sampling
took place. The ivermectin concentration was then measured in the plasma and different tissue samples.
Tissue samples include: hair, fat, skin, lung, liver, intestine and abomasum.
4.2.3 Results of Model Run
The model simulation of ivermectin was done using the data (as described in Chapter 3) for a male goat,
with a ’standardized’ body weight of 19.2 kg. Multiple compartments were modeled: blood, fat, lung,
liver, intestine and abomasum. Hair and skin were are not included in the model and therefore could
not be simulated.
The study by Lespine et al. (2005) shows measured concentrations at 2 days (48 hours), 7 days (168
hours) and 17 days (408 hours) after exposure to ivermectin. The model gave predicted results at 24, 48,
120, 168, 240, 336 and 408 hours after exposure (1, 2, 5, 7, 10, 14 and 17 days). The decision to simulate
internal concentrations for the extra time points was made in order to have a better representation of
the results. The raw results are shown in Table B.1 in Appendix B.
Figures 4.2 through 4.7 show a comparison of measured and predicted results for the modeled compartments.
All compartments, except fat show a similar trend. The predicted and measured concentrations are very
similar to each other 48 hours after exposure. At 168 hours after exposure, the difference increases to the
measured concentrations being 300 - 1200 times higher than the concentrations the model predicts. For
these 5 compartments, concentrations were ’non-detected’ at 408 hours after exposure. For the graphs,
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the assumption was made that this is a concentration of 0.00 µg/mL.
For fat, the difference between the measured and predicted concentrations is higher than for the other
compartments. The measured concentration is 14 times higher than the predicted concentrations at 48
hours after exposure. The difference increases to 6000 times at 168 hours and 1.13*1010 times at 408
hours after exposure. Fat was the only compartment with a detectable amount of ivermectin at the last
measurement.
Figure 4.2: Ivermectin concentration in the plasma. (A) Ivermectin concentration over time. (B)
Ivermectin concentration over time in a semi-logarithmic plot. (C) Predicted concentrations versus
measured concentrations for ivermectin in the plasma. Both axes are on log-scale. The red line shows
the 1:1 line when predicted and measured concentrations match perfectly. The gray lines above and
below represent a deviation of factor 10 of the 1:1 line.
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Figure 4.3: Ivermectin in the adipose tissue. (A) Ivermectin concentration over time. (B) Ivermectin
concentration over time in a semi-logarithmic plot. (C) Predicted concentrations versus measured
concentrations for ivermectin in the adipose tissue. Both axes are on log-scale. The red line shows the
1:1 line when predicted and measured concentrations match perfectly. The gray lines above and below
represent a deviation of factor 10 of the 1:1 line.
Figure 4.4: Ivermectin in the abomasal mucosa. (A) Ivermectin concentration over time. (B)
Ivermectin concentration over time in a semi-logarithmic plot. (C) Predicted concentrations versus
measured concentrations for ivermectin in the abomasal mucosa. Both axes are on log-scale. The red
line shows the 1:1 line when predicted and measured concentrations match perfectly. The gray lines
above and below represent a deviation of factor 10 of the 1:1 line.
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Figure 4.5: Ivermectin in the intestinal mucosa. (A) Ivermectin concentration over time. (B)
Ivermectin concentration over time in a semi-logarithmic plot. (C) Predicted concentrations versus
measured concentrations for ivermectin in the intestinal mucosa. Both axes are on log-scale. The red
line shows the 1:1 line when predicted and measured concentrations match perfectly. The gray lines
above and below represent a deviation of factor 10 of the 1:1 line.
Figure 4.6: Ivermectin in the liver. (A) Ivermectin concentration over time. (B) Ivermectin
concentration over time in a semi-logarithmic plot. (C) Predicted concentrations versus measured
concentrations for ivermectin in the liver. Both axes are on log-scale. The red line shows the 1:1 line
when predicted and measured concentrations match perfectly. The gray lines above and below
represent a deviation of factor 10 of the 1:1 line.
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Figure 4.7: Ivermectin in the lungs. (A) Ivermectin concentration over time. (B) Ivermectin
concentration over time in a semi-logarithmic plot. (C) Predicted concentrations versus measured
concentrations for ivermectin in the lungs. Both axes are on log-scale. The red line shows the 1:1 line
when predicted and measured concentrations match perfectly. The gray lines above and below
represent a deviation of factor 10 of the 1:1 line.
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4.3 Case Study Chloramphenicol
4.3.1 Description of Compound
Chloramphenicol is an antibiotic that can be used against Gram-positive and Gram-
negative bacteria (EFSA CONTAM, 2014). It is used against infections in animals and humans. It is a
natural product, originally coming from the bacterium Streptomyces venezuelae, but is also artificially
mass-produced. The chemical structure of chloramphenicol is shown in Figure 4.8.
Figure 4.8: Chemical Structure of Chloramphenicol (EFSA CONTAM, 2014).
The use of chloramphenicol was banned from the food production chain in the European Union (EU)
in 1994, and is now only allowed in non-food producing animals (EFSA CONTAM, 2014; Hanekamp
& Bast, 2015). In other parts of the world however, such as South-East Asia, it is still widely used.
The ban by the EU was due to the fact that not enough scientific data were available and therefore no
Acceptable Daily Intake (ADI) and Maximum Residu Level (MRL) in food could be established, leading
to a zero-tolerance policy.
Etuk and Onyeyili (2005b) show that chloramphenicol is not or incompletely metabolized by the liver.
The main route of excretion for this compound is renal clearance. There is also evidence that chloramphenicol
is one of few antibiotics that can cross physiological barriers and can therefore enter the brain and
cerebrospinal fluid (Etuk & Onyeyili, 2005b).
4.3.2 Description of Validation Study
The goal of the study by Etuk and Onyeyili (2005b) was to compare the distribution of chloramphenicol
in tissues between healthy and Salmonella typhimurium infected goats, after intravenous treatment. A
group of 54 red Sokoto goats of mixed gender were used, with weights ranging from 15.0 to 25 kilograms
(mean = 18.3kg). Two groups of 24 goats each were made, one consisting of healthy goats, while the
second group was infected with Salmonella typhimurium. These goats were given a dose of 25 mg
chloramphenicol per kilogram body weight intravenously. Two goats of each group were sacrificed at
different time intervals, to collect tissue samples for testing. Ten grams of the following tissues were
collected: liver, skeletal muscle, brain, lungs, kidney, spleen and bone marrow. For the validation of this
PBK model, the data collected from the group of healthy animals were used.
4.3.3 Results of Model Run
The model simulation of chloramphenicol was done using the data (as described in Chapter 3) for mixed
goats, with a ’standardized’ body weight of 17.8 kg. Multiple compartments were simulated: liver,
kidney, heart, lungs, brain and (skeletal) muscle. In the validation study, spleen and bone marrow were
also measured but these compartments are not included in the model and were therefore not simulated.
The case study by Etuk and Onyeyili (2005b) measured chloramphenicol concentrations at 11 time points,
namely 0.08, 0.25, 0.50, 1.00, 3.00, 6.00, 12.00, 24.00, 48.00, 120.00 and 240.00 hours. The model gave
results for the same time points. The results are shown in Table B.2 in Appendix B.
Figures 4.8 through 4.14 show a comparison between the measured and predicted
concentrations for chloramphenicol for the different compartments. Two patterns can be distinguished.
In the first pattern, the predicted concentration initially increases and only decreases after a certain time
after exposure. This is the case for the brain, heart, liver and lungs. The turning point is between 6
and 12 hours after exposure. For the other two compartments, namely muscle and kidney, the predicted
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concentrations decrease from the first data point (at t = 0.08 h) to the last data point (at t = 240 h).
Differences between the measured and predicted concentrations range from being similar to the measured
concentrations being a factor of 180 larger than predicted.
Figure 4.9: Chloramphenicol in the brain. (A) Chloramphenicol concentration over time. (B)
Chloramphenicol concentration over time in a semi-logarithmic plot. (C) Predicted concentrations
versus measured concentrations for chloramphenicol in the brain. Both axes are on log-scale. The red
line shows the 1:1 line when predicted and measured concentrations match perfectly. The gray lines
above and below represent a deviation of factor 10 of the 1:1 line.
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Figure 4.10: Chloramphenicol in the heart. (A) Chloramphenicol concentration over time. (B)
Chloramphenicol concentration over time in a semi-logarithmic plot. (C) Predicted concentrations
versus measured concentrations for chloramphenicol in the heart. Both axes are on log-scale. The red
line shows the 1:1 line when predicted and measured concentrations match perfectly. The gray lines
above and below represent a deviation of factor 10 of the 1:1 line.
Figure 4.11: Chloramphenicol in the kidney. (A) Chloramphenicol concentration over time. (B)
Chloramphenicol concentration over time in a semi-logarithmic plot. (C) Predicted concentrations
versus measured concentrations for chloramphenicol in the kidney. Both axes are on log-scale. The red
line shows the 1:1 line when predicted and measured concentrations match perfectly. The gray lines
above and below represent a deviation of factor 10 of the 1:1 line.
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Figure 4.12: Chloramphenicol in the liver. (A) Chloramphenicol concentration over time. (B)
Chloramphenicol concentration over time in a semi-logarithmic plot. (C) Predicted concentrations
versus measured concentrations for chloramphenicol in the liver. Both axes are on log-scale. The red
line shows the 1:1 line when predicted and measured concentrations match perfectly. The gray lines
above and below represent a deviation of factor 10 of the 1:1 line.
Figure 4.13: Chloramphenicol in the lungs. (A) Chloramphenicol concentration over time. (B)
Chloramphenicol concentration over time in a semi-logarithmic plot. (C) Predicted concentrations
versus measured concentrations for chloramphenicol in the lungs. Both axes are on log-scale. The red
line shows the 1:1 line when predicted and measured concentrations match perfectly. The gray lines
above and below represent a deviation of factor 10 of the 1:1 line.
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Figure 4.14: Chloramphenicol in the muscle. (A) Chloramphenicol concentration over time. (B)
Chloramphenicol concentration over time in a semi-logarithmic plot. (C) Predicted concentrations
versus measured concentrations for chloramphenicol in the muscle. Both axes are on log-scale. The red
line shows the 1:1 line when predicted and measured concentrations match perfectly. The gray lines
above and below represent a deviation of factor 10 of the 1:1 line.
4.4 Case Study Moxifloxacin
4.4.1 Description of Compound
The third compound chosen to use for the validation is moxifloxacin. Moxifloxacin is a fluoroquinolone
antibiotic, that, like chloramphenicol, can be used to treat a large range of Gram-positive and Gram-negative
bacteria, anaerobes and atypical organisms (Barman Balfour & Wiseman, 1999; Fernández-Varón et al.,
2006; Goudah, 2008; Keating & Scott, 2004).
Most common used routes of exposure are oral, intravenous and subcutaneous. The route that is used,
strongly impacts the efficiency of the moxafloxacin (Fernández-Varón et al., 2006). Another important
factor is the dosage used for treatment (Goudah, 2008). Studies show that there are differences in
the pharmacokinetics of moxifloxacin between lactating and non-lactating animals of the same species
(Fernández-Varón et al., 2006). Therefore this has to be taken into consideration when dosages are
extrapolated between lactating and non-lactating individuals of the same species.
Moxifloxacin is metabolized into two metabolites: M1 (sulpho-compound) and M2 (acyl-
glucuronide) (Stass & Kubitza, 1999). The metabolite M1 strongly binds to plasma proteins (90%) and
is mainly excreted in the feces. The second metabolite, M2, does not bind to plasma proteins as much
(only 5%), and is mainly excreted in the urine. Figure 4.9 shows the metabolism of moxifloxacin. Around
20% of the dose of moxifloxacin is excreted without being metabolized, as the parent compound.
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Figure 4.15: Chemical Structure of Moxifloxacin and its metabolites (Stass & Kubitza, 1999).
4.4.2 Description of Validation Study
The aim of the study by Fernández-Varón et al. (2006) was to determine the plasma pharmacokinetics
and penetration of moxifloxacin from blood to milk in lactating goats, after it was given intravenously
or subcutaneously. Six female goats were used in this study, weighing between 32.1 and 52 kilograms.
They were administered a single dosage of 5 mg moxifloxacin per kilogram of body weight. Blood and
milk samples were collected at specific time intervals after the drug was given and the concentration of
moxifloxacin in these samples was determined using modified high performance liquid chromatography
(Fernández-Varón et al., 2006).
4.4.3 Results of Model Run
The model simulation of moxifloxacin was done using the data (as described in Chapter 3) for a female
goat, with a ’standardized’ body weight of 16.8 kg. Only two compartments were simulated for this
model run, namely plasma and milk. This is also the case for the validation study. In the study by
Fernández-Varón et al. (2006), the concentration of moxifloxacin in the plasma was measured at 0, 5,
10, 15, 30 and 45 minutes after exposure, and at 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 32, 48 and 72 hours after
the drug was administered. The concentration in the milk was measured at 2, 4, 6, 8, 10, 24, 32, 48 and
72 hours after exposure. The udder was emptied at the start of the measurements and at every time point.
Figure 4.16 shows the measured and predicted moxifloxacin concentrations in plasma. The predicted and
measured concentrations for plasma are similar until 6 hours after exposure. After 6 hours, the measured
concentration decreases much faster than the predicted concentrations. The modeled concentrations
remain higher (up to 100 times at t = 12 hours after exposure) than those measured in the study by
Fernández-Varón et al. (2006). Figure 4.17 shows a similar trend for the concentration of moxifloxacin in
milk over time. For the first points, at t = 2 and t = 4 hours after exposure, the predicted concentrations
are 3 - 5 times higher than the measured concentrations. This difference increases to factor 20 at 6 hours
after exposure, and continues to increase to the predicted concentration being around 200 times larger
than the measured concentration at 32 hours after exposure.
31
Figure 4.16: Moxifloxacin in the plasma. (A) Moxifloxacin concentration over time. (B) Moxifloxacin
concentration over time in a semi-logarithmic plot. (C) Predicted concentrations versus measured
concentrations for moxifloxacin in the plasma. Both axes are on log-scale. The red line shows the 1:1
line when predicted and measured concentrations match perfectly. The gray lines above and below
represent a deviation of factor 10 of the 1:1 line.
Figure 4.17: Moxifloxacin in the milk. (A) Moxifloxacin concentration over time. (B) Moxifloxacin
concentration over time in a semi-logarithmic plot. (C) Predicted concentrations versus measured
concentrations for moxifloxacin in the milk. Both axes are on log-scale. The red line shows the 1:1 line
when predicted and measured concentrations match perfectly. The gray lines above and below





First the results presented in Chapter 4 are discussed. In Section 5.2 conclusions are drawn based on
this discussion. Here, the main research question is also answered. The chapter finalizes with several
recommendations.
5.1 Discussion
This section discusses the steps that were taken to adjust the generic PBK model platform (Lautz et al.,
2017) to represent the goat. The adjustments, assumptions, parametrization and validation are looked
at to ultimately answer the main research question in the conclusion section of this chapter.
5.1.1 Model Parametrization and Implementation
In order to implement the model, values had to be determined for all model input parameters. This was
done using multiple literature studies. Finding suitable values was sometimes difficult because of the
limited amount of studies done on goats. As explained in Section 3.2, for the physiological parameters
where no data was available for goats, values of sheep were used or informed assumptions were made. The
general assumption is that sheep and goats are sufficiently similar. However, on specific physiological
properties the two species differ. These include the body weight fractions of the carcass, blood, fat,
muscle and mammary gland and the fractions of the cerebral, cardiac, intestinal, renal, pulmonary and
muscular blood flows. This could influence the described ADME-processes and results of the model
(Clewell & Clewell, 2008).
As described in Section 2.2.1, Lautz et al. (2017) assume a blood flow-limited model. This shows that
the blood flow through a tissue is an important factor in the accuracy of the model. The differences in
blood flow fractions between goats and sheep could therefore result in deviating concentrations predicted
by the goat-adjusted model. By adjusting these values to more accurately fit the goat physiology, the
results of the model would likely also become more accurate.
Another factor influencing the results is missing data for several parameters, namely fbile, Vmax, fbact and
Km. Clewell and Clewell (2008) mention that it is difficult to measure these in vitro or in vivo, leading
to this data often being unobtainable. Due to the lack of data, these were set on ’0’ or as ’Not Available’.
Because of this, the metabolism process might not be accurately modeled in the current goat-adjusted
model.
Parameters fbile and fbact determine to what extent enterohepatic circulation takes place. Setting these
parameters to 0, effectively means that this process is negligible in the current model. However, studies
show that enterohepatic circulation does play a role in the metabolizing process of the compounds used
in this thesis (De Smet et al., 2012; Duthaler et al., 2020; Tsai et al., 1999). It is unclear how large
the impact of this process could be on the results as predicted by the model. However, it is a definite
possibility that the unavailability of enterohepatic recycling in the model influenced the results and
adding this process would increase the quality of the predicted results.
Vmax and Km are parameters that are used to simulate the metabolism process in organs. However, values
for these parameters are often lacking. The current model uses (hepatic) clearance as an alternative to
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describe the metabolism process. The hepatic metabolism differs significantly between species (Lautz et
al., 2017). Using hepatic clearance in the model likely influenced the predicted results for chloramphenicol.
Because this compound is not or incompletely metabolized in the liver, hepatic clearance does not
accurately describe its metabolism process. This is not the case for ivermectin and moxifloxacin, as
these are mostly metabolized in the liver. Therefore, for these compounds hepatic clearance can be used
to accurately predict internal concentrations by the PBK model.
5.1.2 Model Validation
The validation studies should give data regarding the tissue distribution of the compound. Especially
important were the compound concentrations in blood, liver, urine, and other compartments. There
were very few available studies on goats that fit this criterion. The few acquirable compounds limited
the opportunity to accurately validate the goat-adjusted PBK model. The values for the toxicokinetic
parameters and rates, namely kabs, Clrenal and Clhepatic, were estimated using allometric scaling due to
the lack of available goat data. Data from sheep and cattle were used for this allometric scaling. These
estimations could be not sufficiently accurate.
The hepatic clearance rates for ivermectin and moxifloxacin were extrapolated using allometric scaling.
As hepatic clearance plays an important role in metabolizing these compounds, the allometric scaling
should not have been applied. This error could be a cause for the found differences between the predicted
and measured concentrations for these compounds.
The results of Chapter 4 show that the current goat-adjusted PBK model can, to a certain extent,
accurately predict the distribution of compounds into different compartments in the goat. For each
of the compounds looked at, a large part of the predicted concentrations were within factor 10 of the
measured concentrations. For ivermectin, 41% of the predictions were within a factor 10 of the measured
values. For chloramphenicol, 53% of the predictions were within a factor 10 of the measured values. For
moxifloxacin, 55% of the predictions were within a factor 10 of the measured values.
For all modeled compounds however, the results were only partly similar to the measured concentrations.
This has to do with specific physicochemical characteristics of the
compounds that are not correctly taken into consideration in the model. The model assumes that the
rate of uptake of the compounds are flow-limited. This is not always an accurate assumption, as the
uptake of compounds can be impacted by other factors (Clewell & Clewell, 2008). These factors influence
biological processes such as storage of the compounds or penetration of the blood-brain or blood-milk
barriers. These physicochemical characteristics and biological processes are not explicitly taken into
account in the current model, which may explain the divergent results. The effects of these factors are
discussed per compound in the following sections.
Ivermectin
In the study by Lespine et al. (2005), the concentration of ivermectin in fat tissue is significantly higher
than in the other tissues. This could be explained by storage of ivermectin in fat tissue. Ivermectin has
high lipid solubility, which could lead to the compound being stored in fat tissue. It can then slowly be
released into the body (Lanusse et al., 1997, Lespine et al., 2005 and Mestorino et al., 2003).
Other studies give similar explanations for the distribution of ivermectin. The study by Begone Ndong et
al. (2007) shows sex-dependent differences between the pharmacokinetic values for ivermectin in sheep.
The values for female sheep are 68.7% higher than those for male sheep. Their main explanation for this
difference, is the difference in fat between male and female sheep. The fat tissue then works as storage
for the ivermectin, leading to a longer residence time in the body.
A study by Cerkvenik et al. (2002) looked at the levels of ivermectin in plasma and milk in lactating
sheep. They found an increasing ivermectin milk to plasma concentration over time. This was due to
the increase in milk fat over time (Cerkvenik et al., 2002). This conclusion was drawn based on the high
lipophilicity of ivermectin, influencing its distribution throughout the body and the milk.
The current PBK model does not accurately describe how the adipose tissue retains ivermectin. This
could explain the lower predicted ivermectin concentration in fat tissue, when compared to the measured
concentration. In addition, the storage in fat tissue leads to a slower release of ivermectin into other parts
of the body. This would explain why the measured concentrations in the other compartments decrease
at a slower rate than the PBK model predicts. There are two possible reasons for this inaccuracy. The
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first is that the fraction of adipose tissue is underestimated. This would mean that there is more adipose
tissue and therefore more ivermectin can be stored.
The other possibility is that it takes more time for ivermectin to be released into the blood from the
adipose tissue than is described. The current model assumes an instant equilibrium between blood and
organ tissue. The high Kow value (1584.89) of ivermectin would lead to a slow release of this compound
from adipose tissue into blood and to an underestimation of the concentration over time by the current
PBK model. Adjusting the model to more accurately describe this process of slow release, would lead to
more fitting results at later exposure phases.
There are multiple administration routes for ivermectin, including orally, subcutaneously and via topical
administration (Lespine et al., 2005). Oral administration is possible through tablets or solution (Mestorino
et al., 2003). The case study by Lespine et al. (2005) makes use of an ivermectin solution. In the
goat-adjusted PBK model, it is not specified whether a solution or tablets are used, which could cause
different results.
Mestorino et al. (2003) compared the results of ivermectin given to sheep orally, using tablets and
solution. Plasma samples were taken at different intervals, ranging from 0.5 to 20 days after exposure.
The study showed an absorption rate (kabs) of 0.001 min
-1 for administration using an oral solution. The
kabs for administration using oral tablets was about half of this at 5.80*10
-4 min-1. The elimination rate
constants of the two routes were however similar to each other (1.33*10-4 and 1.30*10-4 for solution and
tablets respectively) (Mestorino et al., 2003).
The current goat-adjusted PBK model works with an absorption rate constant (kabs) for ivermectin of
0.002 min-1. This is double the value that Mestorino et al. (2003) found for the oral solution and a factor
4 higher for the oral tablets. If assumed that the results of Lespine et al. (2005) have an absorption rate
equal to the one found by Mestorino et al. (2003) (0.001 min-1), the modeled absorption is twice as fast
as the validation study. This means that twice the amount of compound is absorbed by the gut tissue
from the gut lumen. This leads to higher predicted ivermectin concentrations in the gut and liver, in
comparison to the measured concentrations. This does, however, not show in the results, as the predicted
concentrations for the liver and intestinal mucosa are in fact lower than the measured concentrations.
This means that the higher absorption rate constant is not the crucial factor causing the differences in
the results.
Chloramphenicol
For the brain, heart, liver and lungs, the predicted concentrations of chloramphenicol initially increase
and start decreasing after t = 6 hours after exposure. This is not the case for the measured concentrations,
which immediately decrease (Etuk & Onyeyili, 2005b). This indicates that the modeled absorption rate
(0.0889 min-1) is too slow.
Other studies show faster absorption rates. A study by Abdullah and Baggot (1986), shows an absorption
rate constant of 0.0954 min-1. Another study by Etuk et al. (2005) gives an absorption rate of 0.110
min-1. A higher absorption rate (kabs) means faster chloramphenicol uptake by the gut. This influences
the distribution throughout the body, and therefore leads to higher concentrations in other compartments
sooner after exposure starts.
The brain is the only compartment where the predicted concentrations are higher than the measured
concentrations at all points in time after exposure. The difference ranges from factor 12 to a factor
171 higher. An explanation could be the transfer of chloramphenicol through the blood-brain barrier
(BBB). Criteria for a compound to transfer over the BBB in significant amounts are high lipid solubility
and a low molecular weight (< 600 Da) (Banks, 2009; Pardridge, 1995). Chloramphenicol has both
these characteristics and therefore can cross the BBB both actively and passively. This is confirmed by
multiple literature sources, including Das and Patra (2017) and Moffa and Brook (2015).
The current PBK model however, does not explicitly take this transfer over the blood-brain barrier
into account but treats the brain as any other compartment. This could explain the relatively large
differences between the predicted and measured concentrations in the brain. If the processes of passive
and active transfer over the BBB are more accurately defined in the model, this would limit the amount
of compound that transfers over the BBB, leading to lower predicted concentrations. The predicted
concentrations would then likely come closer to the measured concentrations.
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The high lipid solubility of chloramphenicol could also lead to storage in the liver and adipose tissue.
This could explain why the measured concentrations in the liver are much higher in comparison to the
other compartments and shows a relatively high concentration after 120 hours after exposure. As is the
case for ivermectin, the PBK model does not accurately describe the time needed for the compound
to be released from the liver and adipose tissue into the blood. This could explain why the predicted
concentrations in the liver do not differ as much from the other compartments, as is the case for the
measured concentrations.
Moxifloxacin
After 6 hours of exposure, the predicted moxifloxacin concentrations increase to being a factor 100 to 200
larger than the concentrations measured by Fernández-Varón et al. (2006). As is the case with ivermectin
and chloramphenicol, moxifloxacin is also stored in the liver and adipose tissue and released into the
blood. This release is slower than the model simulates. This leads to the measured concentrations in the
blood and milk to be lower than the predicted concentrations in these compartments.
Multiple studies report that there are differences in the pharmacokinetics of
fluoroquinolones, such as moxifloxacin, between lactating and non-lactating individuals of the same
species (Cárceles et al., 2007, Cárceles et al., 2009, Fernández-Varón et al., 2006, Soback et al., 1994).
The current model does not distinguish between lactating and non-lactating individuals of the same
species. This could be an explanation for the increasing differences between the measured and predicted
concentrations.
Moxifloxacin penetrates from the blood into the milk and is then excreted from the body through the milk.
This explains the higher concentrations in the milk in comparison to the plasma that are found in the
model as well as the validation study. Moxifloxacin is an amphoteric compound with multiple pKa values
between 6.4 and 9.5. As goat milk has a pH of 6.6 to 6.8, moxifloxacin crosses the blood-milk barrier easily
through (passive) diffusion and (active) ion-trapping (Cárceles et al., 2007, Fernández-Varón et al., 2006).
The current PBK model does not explicitly take the blood-milk barrier into consideration. This could
be another explanation for the higher predicted concentrations and the increasing differences to the
measured moxifloxacin concentrations. Adding a description of the blood-milk barrier into the model,
might lead to more accurate results. However, as moxifloxacin easily crosses the blood-milk barrier, it
is unclear how much influence adding the transfer processes to the model will have on the differences
between the measured and predicted concentrations in the milk.
5.2 Conclusions and Recommendations
The aim of this study was to adjust the existing PBK model platform developed by Lautz et al. (2017),
to accurately describe the internal dose of compounds in the goat. In addition, the model should be
generic: usable for multiple compartments and compounds. This led to the main research question: Can
the available PBK model structure for farm animals as developed by Lautz et al. (2017) be adapted and
parameterized to result in a PBK model for goats that can be used to accurately describe the internal
dose of compounds in these animals? In conclusion, the current PBK model accurately (within a factor of
10) predicts concentrations in the early exposure phases. This is however, not the case for all compounds
and specific biological processes. At later exposure phases, the model becomes inaccurate, for example
due to delayed excretion of compounds.
The main reason for this is the lack of available data on goats. For 17 out of 33 of the physiological
parameters, values of sheep were used for one or multiple of the gender categories. Missing toxicokinetic
parameters, such as absorption rate constants and clearance rates, were calculated from sheep and
cattle data, using allometric scaling. In addition, for several parameters, data were completely lacking.
Because of this lack of suitable parameter values in existing literature, the results of the validation of
the goat-adjusted PBK model in its current form are disappointing. Some values, such as Vmax and km,
are currently completely missing, making an accurate description of the metabolism process impossible.
This is also the case for the other species this model was developed for, such as cattle, sheep and chicken.
Hepatic clearance is used as an alternative for this process in the current model. This choice could lead
to inaccurate results by the current model.
In addition to the missing parameter values, the lack of sufficient validation studies leads to difficulty
answering the research question. The reason for this, is that there are too few studies showing the tissue
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distribution of compounds in goats and therefore cannot be used to determine whether the predictions
are accurate. The available studies showed another point, namely that several biological processes,
such as the transfer of compounds over the blood-brain and blood-milk barriers and their storage in fat
tissue, are not taken into account in the current PBK model. This leads to an inaccurate description of
concentrations over time in several tissues.
Overall, it is recommended to decrease the knowledge gaps and adjust the model to more accurately
fit biological processes. Research to define values for parameters related to the metabolism process
is necessary in order to be able to describe this process accurately in the model. Additionally, more
knowledge is needed to adjust the model to fit other biological processes, such as the transfer of
compounds over the blood-brain barrier, blood-milk barrier and the storage of chemicals in (adipose)
tissue. Differences between the genders should also be taken into account. These processes are recommended
to be added into the current model as well. Finally, more experimental data is necessary to validate
the PBK model. If these knowledge gaps are decreased and the model is accurately adjusted, the use of
PBK models can be greatly increased in risk assessment. This can lead to a decrease in animals needed
for testing and therefore overall animal welfare.
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(2002). Ivermectin pharmacokinetics in lactating sheep. Veterinary Parasitology, 104 (2), 175–185.
doi:10.1016/S0304-4017(01)00612-4
Chiu, W. A., Barton, H. A., Dewoskin, R. S., Schlosser, P., Thompson, C. M., Sonawane, B., . . . Krishnan,
K. (2007). Evaluation of physiologically based pharmacokinetic models for use in risk assessment.
Journal of Applied Toxicology, 27, 218–237. doi:10.1002/jat.1225
Clark, L. H., Setzer, R. W., & Barton, H. A. (2004). Framework for evaluation of physiologically-based
pharmacokinetic models for use in safety or risk assessment. Risk Analysis, 24 (6), 1697–1717.
doi:10.1111/j.0272-4332.2004.00561.x
Clewell, R. A., & Clewell, H. J. (2008). Development and specification of physiologically based pharmacokinetic
models for use in risk assessment. Regulatory Toxicology and Pharmacology, 50 (1), 129–143. doi:10.
1016/j.yrtph.2007.10.012
Das, B., & Patra, S. (2017). Antimicrobials: Meeting the Challenges of Antibiotic Resistance Through
Nanotechnology. In A. Ficai & A. M. Grumezescu (Eds.), Nanostructures for antimicrobial therapy:
A volume in micro and nano technologies (1st ed., Chap. 1, pp. 1–22). Elsevier.
De Smet, J., Colin, P., De Paepe, P., Ruige, J., Batens, H., Van Nieuwenhove, Y., . . . Boussery, K.
(2012). Oral bioavailability of moxifloxacin after Roux-en-Y gastric bypass surgery. Journal of
Antimicrobial Chemotherapy, 67 (1), 226–229. doi:10.1093/jac/dkr436
Di Giantomasso, D., Morimatsu, H., May, C. N., & Bellomo, R. (2004). Increasing Renal Blood Flow.
Chest, 125 (6), 2260–2267. doi:10.1378/chest.125.6.2260
38
Duthaler, U., Leisegang, R., Karlsson, M. O., Krähenbühl, S., & Hammann, F. (2020). The effect of food
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and milk penetration of moxifloxacin after intravenous and subcutaneous administration to lactating
goats. Veterinary Journal, 172 (2), 302–307. doi:10.1016/j.tvjl.2005.04.017
Goudah, A. (2008). Disposition kinetics of moxifloxacin in lactating ewes. The Veterinary Journal, 178,
280–285. doi:10.1016/j.tvjl.2007.08.007
Gregory, N. G., Christopherson, R. J., & Lister, D. (1986). Adipose tissue capillary blood flow in relation
to fatness in sheep. Research in veterinary science, 40 (3), 352–356. doi:10.1016/s0034-5288(18)
30549-6
Grimes, J. M., Buss, L. A., & Brace, R. A. (1987). Blood volume restitution after hemorrhage in
adult sheep. American Journal of Physiology - Regulatory Integrative and Comparative Physiology,
253 (4). doi:10.1152/ajpregu.1987.253.4.r541
Hales, J. R. S. (1973). Effects of exposure to hot environments on total and regional blood flow in
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# p r o b a b i l i s t i c #
# mult i=compartment model f o r #
# v e t e r i n a r y s p e c i e s #
#===================================#
#load one compartment model code
source ( ’ singchemdmdtSary .R ’ )
l ibrary ( ’ s e n s i t i v i t y ’ )
l ibrary ( ’ reshape ’ )
l ibrary ( ’ ggp lot2 ’ )
#d e f i n e your working d i r e c t i o n s
#i n s t a l l l i b r a r i e s
#i n s t a l l . packages (” s e n s i t i v i t y ”)
#load l i b r a r i e s
#l i b r a r y ( ’ s e n s i t i v i t y ’ )
#Loading p h y s i o l o g y data
fBW <= read . csv ( ” data fBW animals1 . csv ” , s t r i ng sAsFac to r s = FALSE) #organ f r a c t i o n s , i n c l var=d i s t r i b u t i o n parameters
fCO <= read . csv ( ” data fCO animals1 . csv ” , s t r i ng sAsFac to r s = FALSE) #blood f l o w f r a c t i o n s , i n c l var=d i s t r i b u t i o n parameters
r a t e s <= read . csv ( ” data r a t e s animals1 . csv ” , s t r i ng sAsFac to r s = FALSE) #p h y s i o l o g i c a l r a t e s ( not chemical=dependent )
fPC <= read . csv ( ” data pc t i s s u e 1 . csv ” , s t r i ng sAsFac to r s = FALSE) #t i s s u e composit ion , f i x e d during var=a n a l y s i s
#Loading TK data
TK <= read . csv ( ” data TK1. csv ” , s t r i ng sAsFac to r s=FALSE) #t o x i c o k i n e t i c parameters
#Loading phys i cochemica l data
chem <= read . csv ( ” data chem1 . csv ” , s t r i ng sAsFac to r s = FALSE) #phys icochemica l parameters
# Inputs ====
#Def in ing the exposure s c e n a r i o
s p e c i e s <= ” goat g” #s e l e c t the animal
chemical <= ” chloramphenico l ” #s e l e c t chemica l
regime <= ” bo lus ” #exposure regime ( b o l u s /cont inuous )
II
route <= ” iv ” #exposure route ( o r a l / i v )
E dose <= 25 #exposure dose (mg/kgbw )
E start <= 0 #s t a r t o f exposure phase ( h )
E end <= 250 #end o f exposure phase ( h )
E i n t <= 249 #i n t e r v a l between doses ( h ) ; on ly r e l e v a n t when regime=”b o l u s ” or i v
#Simulat ion parameters f o r monte c a r l o
A type <= ”VA” #type o f p r o b a b i l i s t i c a n a l y s i s (”SA” or ”VA”) , f o r i n d i v i d u a l s s k i p t h i s
chem f ix <= TRUE #keep i t TRUE
n sim <= 1000 #number o f i t e r a t i o n s
n boot <= 1000 #number o f boos t rap i t e r a t i o n s ( f o r SA)
#d e f i n e output parameters and time
n out <= 7 #number o f compartments to output ( b lood , l i v e r , kidney , e t c . )
t start <= 0 #s t a r t o f s i m u l a t i o n ( h )
t end <= 240 #end o f s i m u l a t i o n ( h )
#a l l t ime p o i n t s f o r a n a l y s i s ( h ) , on ly r e l e v a n t when chem f i x=TRUE
t A <= c ( 0 . 0 8 , 0 . 25 , 0 . 5 , 1 , 3 , 6 , 12 , 24 , 48 , 120 , 240)
#t A <= c ( seq ( 0 . 0 2 5 , 0 . 2 2 5 , by =0.025) , seq (0 .25 ,24 , by =0.25))
#==============================================================================================
#Setup s i n g l e animal s imula t ion=====
Names f ix <= c ( ”BW” ,
paste ( ”fBW” ,colnames (fBW[2+3*c ( 1 : 1 9 ) ] ) , sep=” ” ) ,
”CO” ,
paste ( ”fCO” ,colnames (fCO[2+3*c ( 1 : 1 9 ) ] ) , sep=” ” ) ,
colnames ( r a t e s [2+3*c ( 0 : 4 ) ] ) ,
colnames ( fPC [ 2 : 5 7 ] ) ,
” n l ” , ” p l ” , ”pr” , ”w” ,
colnames (TK[ 3 : 8 ] ) ,
colnames ( chem [ 2 : 5 ] ) )
NP f ix <= length (Names f ix ) #number o f f i x e d parameters
f ix in <= cbind (fBW[fBW$ s p e c i e s==spe c i e s , ”BW” ] ,
fBW[fBW$ s p e c i e s==spe c i e s , colnames (fBW)%in%substr (Names f ix [ grep ( ’fBW ’ ,Names f ix ) ] ,
start =5,stop=nchar (Names f ix [ grep ( ’fBW ’ ,Names f ix ) ] ) ) ] ,
fCO [ fCO$ s p e c i e s==spe c i e s , ”CO” ] ,
fCO [ fCO$ s p e c i e s==spe c i e s , colnames (fCO)%in%substr (Names f ix [ grep ( ’ fCO ’ ,Names f ix ) ] ,
start =5,stop=nchar (Names f ix [ grep ( ’ fCO ’ ,Names f ix ) ] ) ) ] ,
III
r a t e s [ r a t e s$ s p e c i e s==spe c i e s , colnames ( r a t e s )%in%Names f ix ] ,
fPC [ fPC$ s p e c i e s==spe c i e s , colnames ( fPC)%in%Names f ix ] ,
data . frame ( n l =1, p l =1,pr=1,w=1) ,
TK[TK$ s p e c i e s==s p e c i e s&TK$chemical==chemical , colnames (TK)%in%Names f ix ] ,
chem [ chem$chemical==chemical , colnames ( chem)%in%Names f ix ] )
colnames ( f ix in ) <= Names f ix
par in <= f ix in
#==============================================================================================
#Set up p r o b a b i l i s t i c s imu la t ions====
i f ( chem f ix & A type==”SA” ) {
#S e n s i t i v i t y a n a l y s i s wi th f i x e d chem parameters and vary ing p h y s i o l o g y
#i n i t i a l l i s t wi th names o f a l l vary ing parameters
Names var <= c ( ”BW” ,
paste ( ”fBW” ,colnames (fBW[2+3*c ( 1 : 1 9 ) ] ) , sep=” ” ) ,
”CO” ,
paste ( ”fCO” ,colnames (fCO[2+3*c ( 1 : 1 9 ) ] ) , sep=” ” ) ,
colnames ( r a t e s [2+3*c ( 0 : 4 ) ] ) ,
” n l ” , ” p l ” , ”pr” , ”w” )
#i n i t i a l l i s t wi th median v a l u e s o f a l l vary ing parameters
Medians <= cbind (fBW[fBW$ s p e c i e s==spe c i e s ,2+3*c ( 0 : 1 9 ) ] ,
fCO [ fCO$ s p e c i e s==spe c i e s ,2+3*c ( 0 : 1 9 ) ] ,
r a t e s [ r a t e s$ s p e c i e s==spe c i e s ,2+3*c ( 0 : 4 ) ] ,
data . frame ( n l =1, p l =1,pr=1,w=1))
colnames ( Medians ) <= Names var
Names var not <= colnames ( Medians [ which( Medians==0| i s . na( Medians ) ) ] )
#update d i s t r i b u t i o n parameters f o r vary ing parameters
Medians <= Medians [ ! (colnames ( Medians)%in%Names var not ) ] #e x c l u d e a l l compartments f o r which median = 0 or NA
Lower <= Medians = 0 .1*Medians
Upper <= Medians + 0 .1*Medians
Names var <= colnames ( Medians )
NP var <= length (Names var ) #number o f vary ing parameters
#a l l f i x e d parameters ( i n c l u d i n g ’ vary ing parameters ’ t h a t are 0 or NA)
Names f ix <= c (colnames (TK[ 3 : 8 ] ) ,
colnames ( chem [ 2 : 5 ] ) ,
IV
colnames ( fPC [ 2 : 5 7 ] ) ,
Names var not )
NP f ix <= length (Names f ix ) #number o f f i x e d parameters
f ix in <= cbind (TK[TK$ s p e c i e s==s p e c i e s&TK$chemical==chemical , colnames (TK)%in%Names f ix ] ,
chem [ chem$chemical==chemical , colnames ( chem)%in%Names f ix ] ,
fPC [ fPC$ s p e c i e s==spe c i e s , colnames ( fPC)%in%Names f ix ] ,
fBW[fBW$ s p e c i e s==spe c i e s , colnames (fBW)%in%substr (Names var not [ grep ( ’fBW ’ ,Names var not ) ] ,
start =5,stop=nchar (Names var not [ grep ( ’fBW ’ ,Names var not ) ] ) ) ] ,
fCO [ fCO$ s p e c i e s==spe c i e s , colnames (fCO)%in%substr (Names var not [ grep ( ’ fCO ’ ,Names var not ) ] ,
start =5,stop=nchar (Names var not [ grep ( ’ fCO ’ ,Names var not ) ] ) ) ] ,
r a t e s [ r a t e s$ s p e c i e s==spe c i e s , colnames ( r a t e s )%in%Names var not ] )
colnames ( f ix in ) <= Names f ix
#c r e a t e data frames wi th random samples
X1 <= matrix (NA, nrow = n sim , ncol = NP var )
colnames (X1) <= Names var
X1 <= as . data . frame (X1)
X2 <= matrix (NA, nrow = n sim , ncol = NP var )
colnames (X2) <= colnames (X1)
X2 <= as . data . frame (X2)
for ( i in 1 :NP var ){
X1 [ , i ] <= runif (n sim , min = Lower [ , i ] , max = Upper [ , i ] )
X2 [ , i ] <= runif (n sim , min = Lower [ , i ] , max = Upper [ , i ] )
}
#Sobo l d es i gn
sa <= s obo l j an s en (model = NULL, X1 , X2 , nboot = n boot , conf = 0 . 9 5 )
SARes <= sa$X
} else i f (A type==”SA” ) {
#S e n s i t i v i t y a n a l y s i s wi th f i x e d chem parameters and vary ing p h y s i o l o g y
#i n i t i a l l i s t wi th names o f a l l vary ing parameters
Names var <= c (colnames (TK[ 3 : 8 ] ) ,
colnames ( chem [ 2 : 5 ] ) )
V
#i n i t i a l lower and upper l i m i t s f o r uniform d i s t r i b u t i o n s
Lower <= as . data . frame (cbind ( 0 , 0 , 0 ,NA,NA,NA, 1 0 , 0 . 0 0 1 , 0 . 0 0 0 0 1 , 0 . 0 1 ) )
Upper <= as . data . frame (cbind ( 1 , 1 , 1 ,NA,NA,NA,1000 ,1000 ,10000000000000 ,100000))
colnames ( Lower ) = colnames ( Upper ) = Names var
Names var not <= colnames ( Lower [ which( i s . na( Lower ) ) ] )
Lower <= Lower [ ! (colnames ( Lower)%in%Names var not ) ] #e x c l u d e a l l compartments f o r which median = 0 or NA
Upper <= Upper [ ! (colnames ( Upper)%in%Names var not ) ] #e x c l u d e a l l compartments f o r which median = 0 or NA
Names var <= colnames ( Lower )
NP var <= length (Names var ) #number o f vary ing parameters
#l i s t wi th names o f a l l f i x e d parameters ( i n c l u d i n g ’ vary ing parameters ’ t h a t are 0 or NA)
Names f ix <= c ( ”BW” ,
paste ( ”fBW” ,colnames (fBW[2+3*c ( 1 : 1 9 ) ] ) , sep=” ” ) ,
”CO” ,
paste ( ”fCO” ,colnames (fCO[2+3*c ( 1 : 1 9 ) ] ) , sep=” ” ) ,
colnames ( r a t e s [2+3*c ( 0 : 4 ) ] ) ,
colnames ( fPC [ 2 : 5 7 ] ) ,
” n l ” , ” p l ” , ”pr” , ”w” ,
Names var not )
NP f ix <= length (Names f ix ) #number o f f i x e d parameters
f ix in <= cbind (fBW[fBW$ s p e c i e s==spe c i e s , ”BW” ] ,
fBW[fBW$ s p e c i e s==spe c i e s , colnames (fBW)%in%substr (Names f ix [ grep ( ’fBW ’ ,Names f ix ) ] ,
start =5,stop=nchar (Names f ix [ grep ( ’fBW ’ ,Names f ix ) ] ) ) ] ,
fCO [ fCO$ s p e c i e s==spe c i e s , ”CO” ] ,
fCO [ fCO$ s p e c i e s==spe c i e s , colnames (fCO)%in%substr (Names f ix [ grep ( ’ fCO ’ ,Names f ix ) ] ,
start =5,stop=nchar (Names f ix [ grep ( ’ fCO ’ ,Names f ix ) ] ) ) ] ,
r a t e s [ r a t e s$ s p e c i e s==spe c i e s , colnames ( r a t e s )%in%Names f ix ] ,
fPC [ fPC$ s p e c i e s==spe c i e s , colnames ( fPC)%in%Names f ix ] ,
data . frame ( n l =1, p l =1,pr=1,w=1) ,
TK[TK$ s p e c i e s==s p e c i e s&TK$chemical==chemical , colnames (TK)%in%Names var not ] ,
chem [ chem$chemical==chemical , colnames ( chem)%in%Names var not ] )
colnames ( f ix in ) <= Names f ix
#Change upper l i m i t f o r c l e a r a n c e depending on p h y s i o l o g y o f s p e c i e s o f i n t e r e s t
#r e n a l c l e a r a n c e = b lood f l o w to k idneys
Upper [ , ”Cl r e na l ” ] <= f ix in$fCO kidney * f ix in$CO / f ix in$BW
VI
#h e p a t i c c l e a r a n c e = b lood f l o w to l i v e r ( i n c l p o r t a l a r t e r y )
Upper [ , ”Cl hepat i c ” ] <= ( f ix in$fCO l i v e r+f ix in$fCO i n t e s t i n e )* f ix in$CO/ f ix in$BW
#c r e a t e data frames wi th random samples
X1 <= matrix (NA, nrow = n sim , ncol = NP var )
colnames (X1) <= Names var
X1 <= as . data . frame (X1)
X2 <= matrix (NA, nrow = n sim , ncol = NP var )
colnames (X2) <= colnames (X1)
X2 <= as . data . frame (X2)
for ( i in 1 :NP var ){
X1 [ , i ] <= runif (n sim , min = Lower [ , i ] , max = Upper [ , i ] )
X2 [ , i ] <= runif (n sim , min = Lower [ , i ] , max = Upper [ , i ] )
}
#Sobo l d es i gn
sa <= s obo l j an s en (model = NULL, X1 , X2 , nboot = n boot , conf = 0 . 9 5 )
SARes <= sa$X
} else i f (A type==”VA” ) {
#v a r i a b i l i t y a n a l y s i s wi th f i x e d chemica l and TK parameters
Names var <= c ( ”BW” ,
paste ( ”fBW” ,colnames (fBW[2+3*c ( 1 : 1 9 ) ] ) , sep=” ” ) ,
”CO” ,
paste ( ”fCO” ,colnames (fCO[2+3*c ( 1 : 1 9 ) ] ) , sep=” ” ) ,
colnames ( r a t e s [2+3*c ( 0 : 4 ) ] ) )
#i n i t i a l l i s t wi th mean + sd v a l u e s o f a l l vary ing parameters
Means <= cbind (fBW[fBW$ s p e c i e s==spe c i e s ,2+3*c ( 0 : 1 9 ) ] ,
fCO [ fCO$ s p e c i e s==spe c i e s ,2+3*c ( 0 : 1 9 ) ] ,
r a t e s [ r a t e s$ s p e c i e s==spe c i e s ,2+3*c ( 0 : 4 ) ] )
SDs <= cbind (fBW[fBW$ s p e c i e s==spe c i e s ,3+3*c ( 0 : 1 9 ) ] ,
fCO [ fCO$ s p e c i e s==spe c i e s ,3+3*c ( 0 : 1 9 ) ] ,
r a t e s [ r a t e s$ s p e c i e s==spe c i e s ,3+3*c ( 0 : 4 ) ] )
D i s t r i b u t i o n s <= cbind (fBW[fBW$ s p e c i e s==spe c i e s ,4+3*c ( 0 : 1 9 ) ] ,
fCO [ fCO$ s p e c i e s==spe c i e s ,4+3*c ( 0 : 1 9 ) ] ,
r a t e s [ r a t e s$ s p e c i e s==spe c i e s ,4+3*c ( 0 : 4 ) ] )
colnames (Means ) = colnames (SDs) = colnames ( D i s t r i b u t i o n s ) = Names var
VII
Names var not <= colnames (SDs [ which( i s . na(SDs ) ) ] )
Means <= Means [ ! (colnames (Means)%in%Names var not ) ] #e x c l u d e a l l parameters wi thou t SD
SDs <= SDs [ ! (colnames (SDs)%in%Names var not ) ] #e x c l u d e a l l parameters wi thou t SD
D i s t r i b u t i o n s <= D i s t r i b u t i o n s [ ! (colnames ( D i s t r i b u t i o n s )%in%Names var not ) ] #e x c l u d e a l l parameters wi thou t SD
Names var <= colnames (SDs)
NP var <= length (Names var ) #number o f vary ing parameters
#l i s t wi th names o f a l l f i x e d parameters ( i n c l u d i n g ’ vary ing parameters ’ t h a t are 0 or NA)
Names f ix <= c (colnames ( fPC [ 2 : 5 7 ] ) ,
” n l ” , ” p l ” , ”pr” , ”w” ,
colnames (TK[ 3 : 8 ] ) ,
colnames ( chem [ 2 : 5 ] ) ,
Names var not )
NP f ix <= length (Names f ix ) #number o f f i x e d parameters
f ix in <= cbind ( fPC [ fPC$ s p e c i e s==spe c i e s , colnames ( fPC)%in%Names f ix ] ,
data . frame ( n l =1, p l =1,pr=1,w=1) ,
TK[TK$ s p e c i e s==s p e c i e s&TK$chemical==chemical , colnames (TK)%in%Names f ix ] ,
chem [ chem$chemical==chemical , colnames ( chem)%in%Names f ix ] ,
fBW[fBW$ s p e c i e s==spe c i e s , colnames (fBW)%in%substr (Names f ix [ grep ( ’fBW ’ ,Names f ix ) ] ,
start =5,stop=nchar (Names f ix [ grep ( ’fBW ’ ,Names f ix ) ] ) ) ] ,
fCO [ fCO$ s p e c i e s==spe c i e s , colnames (fCO)%in%substr (Names f ix [ grep ( ’ fCO ’ ,Names f ix ) ] ,
start =5,stop=nchar (Names f ix [ grep ( ’ fCO ’ ,Names f ix ) ] ) ) ] ,
r a t e s [ r a t e s$ s p e c i e s==spe c i e s , colnames ( r a t e s )%in%Names f ix ] )
colnames ( f ix in ) <= Names f ix
#c r e a t e data frames wi th random samples
X1 <= matrix (NA, nrow = n sim , ncol = NP var )
colnames (X1) <= Names var
X1 <= as . data . frame (X1)
SARes <= X1
for ( i in 1 :NP var ){
i f ( D i s t r i b u t i o n s [ i ] == ”N” ) {
SARes [ , i ] <= rnorm(n sim , mean = Means [ , i ] , sd = SDs [ , i ] )
} else i f ( D i s t r i b u t i o n s [ i ] == ”B” ) {
alpha <= ( (1 = Means [ , i ] ) / SDs [ , i ] ˆ2 = 1 / Means [ , i ] ) * Means [ , i ] ˆ 2
beta <= alpha * (1 / Means [ , i ] = 1)
VIII
SARes [ , i ] <= rbeta (n sim , shape1 = alpha , shape2 = beta )
} else i f ( D i s t r i b u t i o n s [ i ] == ”LN” ) {
CV <= SDs [ , i ] /Means [ , i ]
mlog <= log (Means [ , i ] /sqrt(1+CVˆ2)) #mean o f l o g v a l u e s
s l o g <= sqrt ( log(1+CVˆ2)) #sd o f l o g v a l u e s





# Model run f o r p r o b a b i l i s t i c a n a l y s i s ( to be done on s e p a r a t e s e r v e r ) ====
for ( k in 1 : (nrow(SARes)/1000)) {
var in temp <= SARes [ c ((1+1000* (k=1) ) : ( k* 1 0 0 0 ) ) , ]
par in <= cbind (var in temp , f ix in )
#a d j u s t c l e a r a n c e r a t e s o f h y p o t h e t i c a l chemica l s based on v a l u e s drawn f o r p h y s i o l o g y
i f ( chem f ix & ( chemical==”chem1” | chemical==”chem2” | chemical==”chem3” ) ) {
par in$Cl r e na l <= par in$Cl r e na l*par in$fCO kidney*par in$CO / par in$BW
par in$Cl hepat i c <= par in$Cl hepat i c* (par in$fCO i n t e s t i n e+par in$fCO l i v e r )*par in$CO / par in$BW
}
write . csv (par in , f i l e=paste ( ”par in ch ik o r a l 8 . 6 ” , k , ” . csv ” , sep=”” ) ,row .names = FALSE)
}
#===========================================================================
#Model a p p l i c a t i o n=====
#sub in <= 1
source ( ’ singchem dmdt Sary .R ’ )
#par in <= read . csv ( p a s t e (” par in c h i k o r a l 8 . 6 1 . csv ” , sep =””))
SimRes <= matrix (NA, nrow = nrow(par in ) , ncol = n out*length ( t A) )
colnames ( SimRes ) <= c ( paste ( ” blood t ” , t A, sep=”” ) , paste ( ” l i v e r t ” , t A, sep=”” ) , paste ( ” kidney t ” , t A, sep=”” ) ,
paste ( ” bra in t ” , t A, sep=”” ) , paste ( ” heart t ” , t A, sep=”” ) , paste ( ” lung t ” , t A, sep=”” ) , paste ( ” muscle t ” , t A, sep=”” ) )
for ( j in 1 :nrow(par in ) ) {
print ( paste0 ( ”Running loop : ” , j ) )
print ( paste ( ” Current time : ” , Sys . time ( ) ) )
SimRes [ j , ] <= mult i t o o l (
par in = par in [ j , ] , #input data frame
s p e c i e s = spec i e s , regime = regime , route = route , E dose = E dose , E start = E start , E end = E end , E i n t = E int ,
IX
#exposure s c e n a r i o
n out = n out , t start = t start , t end = t end , t A = t A, chem f ix = chem f ix )
}
write . csv ( SimRes , paste ( ” goat ch loramphenico l t ryout . csv ” , sep=”” ) ,row .names = FALSE)
#=======================================================================================================
#Plot Concentrat ions vs time
i v e rmect in lung . data <= read . csv ( f i l e=” ivermect in lung . csv ” )
p1 <= ggp lot (data = ivermect in lung . data , aes ( x = Hours , y = Value , group = Compartment ) ) +
geom point ( aes ( c o l o r = Compartment ) ) +
geom l i n e ( aes ( c o l o r = Compartment ) )
p1 + labs ( t i t l e = ” Ivermect in in Lungs” , x = ”Time a f t e r Exposure ( hours ) ” , y = ” Concentrat ion (\ u03bcg/mL) ” )
#================================================================
#Plot Log measured vs p r e d i c t e d c o n c e n t r a t i o n s
i v e rmect in lung . data <= read . csv ( f i l e=” ivermect in lung2 . csv ” )
p2 <= ggp lot (data = ivermect in lung . data , aes ( x = Measurement , y = Model ) ) +
geom point ( ) +
geom abline ( i n t e r c e p t= 0 , s l ope =1, col=” red ” ) +
geom abline ( i n t e r c e p t=log10 ( 10 ) , s l ope =1, col=” darkgrey ” ) +
geom abline ( i n t e r c e p t = =log10 ( 10 ) , s l ope = 1 , col=” darkgrey ” )
p2 + scale x log10 ( l i m i t s = c (1 e=6,1e=1)) +
scale y log10 ( l i m i t s = c (1 e=6,1e=1)) +
labs ( t i t l e = ” Ivermect in in Lungs” , x = ”Measured concent ra t i on (\ u03bcg/mL) ) ” , y = ” Pred icted concent ra t i on (\ u03bcg/mL) ” )
#================================================================
#Plot l o g c o n c e n t r a t i o n s vs time
i v e rmect in lung . data <= read . csv ( f i l e=” ivermect in lung . csv ” )
p3 <= ggp lot (data = ivermect in lung . data , aes ( x = Hours , y = Value , group = Compartment ) ) +
geom point ( aes ( c o l o r = Compartment ) ) +
geom l i n e ( aes ( c o l o r = Compartment ) )
p3 + scale y log10 ( ) +
labs ( t i t l e = ” Ivermect in in Lungs” , x = ”Time a f t e r Exposure ( hours ) ” , y = ” Concentrat ion (\ u03bcg/mL) ” )
X
dMdt <= function ( i , M, C, h , physnames ,
Qin , Qout , CO, PC, OW,
E bolus , E cont , E iv , kga s t r i c ,
Qbolus , Qingest , Qiv , Qexhale ,
kabs , Vmax, Km, Cl , f b i l e , fbact ,
Qegg , Qmilk ) {
#input v i a food
dMfood <= E bolus [ i ] * Qbolus + E cont [ i ] * Qingest
#input v i a i v
dMiv <= E iv [ i ] * Qiv
#a b s o r p t i o n over i n t e s t i n a l w a l l
dMabs <= M[ physnames==”lumen” ] * kabs
#d e l i v e r y v i a a r t e r i a l b lood
dMart <= Qin * C[ physnames==” ar t ” ]
dMart [ physnames==” ar t ” ] <= =sum( dMart )
#d e l i v e r y to venous b lood and passage through p o r t a l ve in
dMven <= Qout * (C / PC)
dMart [ physnames==” l i v e r ” ] <= dMart [ physnames==” l i v e r ” ] = dMven [ physnames==” i n t e s t i n e ” ]
dMven [ physnames==” l i v e r ” ] <= dMven [ physnames==” l i v e r ” ] + Qout [ physnames==” i n t e s t i n e ” ] * (C[ physnames==” l i v e r ” ] / PC[ physnames==” l i v e r ” ] )
dMven [ physnames==”ven” ] <= =sum(dMven [ physnames !=” i n t e s t i n e ” ] )
#metabolism an e n t e r o h e p a t i c c i r c u l a t i o n and r e t r a n s f o r m a t i o n
dMmet <= i f e l s e ( ! i s . na(Vmax)&! i s . na(Km) , (Vmax* (C/PC) ) / (Km+(C/PC) )*OW, 0 )
dMmet [ physnames==” l i v e r ” ] <= i f e l s e ( ! i s . na( Cl [ physnames==” l i v e r ” ] ) , Cl [ physnames==” l i v e r ” ] *C[ physnames==” l i v e r ” ] )
dMmet [ physnames==”lumen” ] <= =dMmet [ physnames==” l i v e r ” ] * f b i l e * f bac t
dMmet [ physnames==”metab” ] <= =dMmet [ physnames==” l i v e r ” ] = dMmet [ physnames==”lumen” ]
#t r a n s p o r t over lung and e x h a l a t i o n
dMexh <= =CO * C
dMexh [ physnames !=”ven” ] <= 0
dMexh [ physnames==” ar t ” ] <= =dMexh [ physnames==”ven” ] * (CO / (CO + Qexhale * PC[ physnames==” a i r ” ] ) )
dMexh [ physnames==” a i r ” ] <= =dMexh [ physnames==”ven” ] * ( ( Qexhale * PC[ physnames==” a i r ” ] ) / (CO + Qexhale * PC[ physnames==” a i r ” ] ) )
#e x c r e t i o n to urine , milk , eggs , f e c e s
dMexc <= M[ physnames==”lumen” ] * k g a s t r i c
dMexc [ physnames==” kidney ” ] <= C[ physnames==” kidney ” ] * Cl [ physnames==” kidney ” ]
dMexc [ physnames==” reprod ” ] <= C[ physnames==” reprod ” ] * Qegg [ physnames==” reprod ” ]
dMexc [ physnames==”mamgland” ] <= C[ physnames==”mamgland” ] * Qmilk [ physnames==”mamgland” ]
dMexc [ physnames==” ur ine ” ] <= =dMexc [ physnames==” kidney ” ]
dMexc [ physnames==” egg ” ] <= =dMexc [ physnames==” reprod ” ]
dMexc [ physnames==” milk ” ] <= =dMexc [ physnames==”mamgland” ]
dMdt <= dMfood + dMiv + (dMabs + dMart + dMven + dMmet + dMexh + dMexc) * (h / 60)
XI
M <= M + dMdt
C <= i f e l s e (OW==0,0,M/OW)
return ( l i s t (M=M,C=C) )
}
#Function to run model
mult i t o o l <= function (par in , s p e c i e s , regime , route , E dose , E start , E end , E int , n out , t start , t end , t A, chem f ix ) {
#Physicochemica l p r o p e r t i e s ====
MW<= par in$MW
Kow <= par in$Kow #Kow
S <= (0 . 001*par in$S) / MW #s o l u b i l i t y
Temp <= 298 #Temperature 298 K = 25 degC
R <= 8 .314 #Gas cons tant ( J/mol/K)
Pv <= par in$Pv #vapor p r e s s u r e
#General p h y s i o l o g y ====
BW<= par in$BW #bodyweight ( kg )
CO <= par in$CO #c ard iac output (L/min)
i f ( s p e c i e s==” chicken ” ) {
Qexhale <= ( (284 * (BWˆ 0 . 7 7 ) ) /1000) #V e n t i l a t i o n avian (L/min)
} else {
Qexhale <= (0 . 499 * (BWˆ 0 . 8 1 ) ) #V e n t i l a t i o n mammalian (L/min)
}
#one matrix per r e l e v a n t phys parameter ( in r i g h t order )
comp <= colnames (par in [ grep ( ’fBW ’ ,colnames (par in ) ) ] )
comp <= comp [ order (comp ) ]
physnames <= c ( substr (comp , start =5,stop=nchar (comp ) ) , ”ven” , ” a r t ” , ”lumen” , ” milk ” , ” egg ” , ” ur ine ” , ” a i r ” , ” f e c e s ” , ”metab” , ” f e ed ” , ” iv ” )
#Organ w e i g h t s
fBW <= c ( t (par in [ comp ] ) , rep ( 0 , 1 1 ) )
fBW[ physnames==”ven” ] <= 2/3 * fBW[ physnames==” blood ” ]
fBW[ physnames==” ar t ” ] <= 1/3 * fBW[ physnames==” blood ” ]
fBW <= fBW[ physnames !=” blood ” ]
OW<= BW*fBW/sum(fBW) #organ volums (L) , based on normal ized we igh t f r a c t i o n s and o v e r a l l assumed d e n s i t y o f 1 L/kg
XII
#Blood f l o w s Q
comp <= gsub ( ’fBW ’ , ’ fCO ’ ,comp)
fCO <= c ( t (par in [ comp ] ) , rep ( 0 , 1 1 ) )
fCO <= (fCO [ physnames !=” blood ” ] )
Qin <= fCO*CO/sum(fCO) #blood f l o w s (L/min ) , normal ized to CO
Qout <= =Qin
#Tissue=b lood p a r t i t i o n i n g
comp <= c (colnames (par in [ grep ( ’ n l ’ ,colnames (par in ) ) ] ) , colnames (par in [ grep ( ’ p l ’ ,colnames (par in ) ) ] ) ,
colnames (par in [ grep ( ’ pr ’ ,colnames (par in ) ) ] ) , colnames (par in [ grep ( ’ w ’ ,colnames (par in ) ) ] ) )
comp <= comp [ order (comp ) ]
PCcomp <= comp [ c(=grep ( ’ exp ’ , comp) ,=grep ( ’ i n t ’ , comp ) ) ] #a l l t i s s u e composi t ion =names
fPC old <= c ( t (par in [ PCcomp ] ) ) #’ o l d f r a c t i o n s ’
fPC new <= fPC old*c (par in$nl , par in$pl , par in$pr , par in$w) #new f r a c t i o n s
#n orma l i sa t io n to mean sum
sumold <= rep ( tapply ( fPC old , rep ( seq ( length ( fPC old )/4) , each =4) ,sum) , each=4)
sumnew <= rep ( tapply ( fPC new, rep ( seq ( length ( fPC old )/4) , each =4) ,sum) , each=4)
fPC new <= fPC new* ( sumold/sumnew)
PCexps <= comp [ grep ( ’ exp ’ , comp ) ]
fPC exp <= c ( t (par in [ PCexps ] ) ) #a l l QSAR exponents
PCints <= comp [ grep ( ’ i n t ’ , comp ) ]
fPC i n t <= c ( t (par in [ PCints ] ) ) #a l l QSAR i n t e r c e p t s
t i s snames <= c ( substr (PCcomp [ grep ( ’ n l ’ ,PCcomp ) ] , start =1,stop=nchar (PCcomp [ grep ( ’ n l ’ ,PCcomp) ] ) =3))
PC1 <= fPC i n t*fPC new*KowˆfPC exp
PC1 <= tapply ( fPC i n t*fPC new*KowˆfPC exp , rep ( seq ( length (PC1)/4) , each =4) ,sum) #p a r t i t i o n i n g c o e f f i c i e n t s t i s s u e=water
PC <= rep (PC1 [ t i s snames==” blood ” ] , length ( physnames ) )
PC[match( t i ssnames , physnames ) ] <= PC1
PC[ physnames==” a i r ” ] <= (Pv/S)/ (R*Temp)
PC[ physnames==”stomach” | physnames==”abomasum” | physnames==”omasum” | physnames==”rumen” |
physnames==” ret i cu lum ” | physnames==” g i z za rd ” | physnames==” crop ” ] <= PC[ physnames==” i n t e s t i n e ” ]
PC[ i s . na(PC) ] <= PC[ physnames==” blood ” ]
PC <= PC/PC[ physnames==” blood ” ]
PC <= PC[ physnames !=” blood ” ]
#Rates and f l o w s ( not chemical=dependent )
physnames <= physnames [ physnames !=” blood ” ]
XIII
Qingest <= rep (0 , length ( physnames ) )
Qiv <= rep (0 , length ( physnames ) )
Qbolus <= rep (0 , length ( physnames ) )
k g a s t r i c <= rep (0 , length ( physnames ) )
Qmilk <= rep (0 , length ( physnames ) )
Qegg <= rep (0 , length ( physnames ) )
f b i l e <= par in$ f b i l e #f r a c t i o n o f m e t a b o l i t e s r e e n t e r i n g lumen with b i l e (=)
Qingest [ physnames==”lumen” ] <= par in$Qingest / (24*60) #i n g e s t i o n r a t e k g f e e d /min
Qingest [ physnames==” feed ” ] <= =par in$Qingest / (24*60)
Qiv [ physnames==”ven” ] <= 1
Qiv [ physnames==” iv ” ] <= =1
Qbolus [ physnames==”lumen” ] <= 1
Qbolus [ physnames==” feed ” ] <= =1
k g a s t r i c [ physnames==” f e c e s ” ] <= par in$ k g a s t r i c
k g a s t r i c [ physnames==”lumen” ] <= =par in$ k g a s t r i c#g a s t r i c emptying r a t e cons tant (1/min)
Qmilk [ physnames==”mamgland”&Qin !=0 ] <= =par in$Qmilk #milk product ion r a t e (L/min)
Qegg [ physnames==” reprod ”&Qin !=0 ] <= =par in$Qegg #egg product ion r a t e (L/min)
#TK parameters
kabs <= rep (0 , length ( physnames ) )
Vmax <= rep (NA, length ( physnames ) )
Km <= rep (NA, length ( physnames ) )
Cl <= rep (0 , length ( physnames ) )
fbac t <= par in$ f bac t
kabs [ physnames==” i n t e s t i n e ” ] <= par in$kabs
kabs [ physnames==”lumen” ] <= =par in$kabs
Vmax[ physnames==” l i v e r ” ] <= =par in$Vmax tot
Km[ physnames==” l i v e r ” ] <= par in$Km tot
#Cl [ physnames==”l i v e r ” ] <= =par in$Cl h e p a t i c * BW * par in$ i n h i b i t
Cl [ physnames==” l i v e r ” ] <= =par in$Cl hepat i c * BW
Cl [ physnames==” kidney ” ] <= =par in$Cl r e na l * BW
#Time v e c t o r f o r exposure ====
h <= 3 #s t e p s i z e in seconds
t <= seq (3600*t start , 3600*t end ,by=h) #v e c t o r wi th t i m e p o i n t s ( seconds )
#E dose <= par in$E dose #only becuase o f v a r i b i l a i t y in b i o a v a i l a b i l i t y , o t h e r w i s e
#E dose needs to be d e s r c i b e d in mul t i t o o l
XIV
E iv <= rep (0 , t imes=length ( t ) )
E bolus <= rep (0 , t imes=length ( t ) )
E cont <= rep (0 , t imes=length ( t ) )
i f ( route==” o r a l ” & regime == ” bolus ” ) {
E bolus [ t>=E start*3600 & t<3600*E end & t%%(3600*E i n t )==0] <= (E dose/MW)*BW
} else i f ( route==” o r a l ” & regime == ” cont inuous ” ) {
#E cont [ t>=E s t a r t *3600 & t<3600*E end ] <= E dose/MW
E cont [ t>=E start*3600 & t<3600*E end ] <= ( (E dose/MW)/par in$Qingest )*BW #mmol/ k g f e e d
} else {
E iv [ t==E start*3600 ] <= (E dose/MW)*BW
}
M <= rep (0 , length ( physnames ) ) #mass per compartment (mmol)
C <= rep (0 , length ( physnames ) ) #c o n c e n t r a t i o n per compartment (mmol/L)
#Create output s h e e t ====
i f ( chem f ix ) {
r e s u l t s <= matrix (NA,nrow=1,ncol=n out*length ( t A) )
colnames ( r e s u l t s ) <= c ( paste ( ” blood t ” , t A, sep=”” ) , paste ( ” l i v e r t ” , t A, sep=”” ) , paste ( ” kidney t ” , t A, sep=”” ) ,
paste ( ” bra in t ” , t A, sep=”” ) , paste ( ” heart t ” , t A, sep=”” ) , paste ( ” lung t ” , t A, sep=”” ) , paste ( ” muscle t ” , t A, sep=”” ) )
#colnames ( r e s u l t s ) <= c ( p a s t e (” b lood t ” , t A, sep =””))
} else {
r e s u l t s <= matrix (0 ,nrow=1,ncol=3)
colnames ( r e s u l t s ) <= c ( ”Cmax” , ”tmax” , ”AUC 24h” )
}
#Model s i m u l a t i o n ====
for ( i in 1 : length ( t ) ) {
output <= dMdt( i=i , M=M, C=C, h=h , physnames=physnames , Qin=Qin , Qout=Qout , CO=CO,
PC=PC, OW=OW, E bolus=E bolus , E cont=E cont , E iv=E iv , k g a s t r i c=kga s t r i c ,
Qbolus=Qbolus , Qingest=Qingest , Qiv=Qiv , Qexhale=Qexhale , kabs=kabs , Vmax=Vmax,
Km=Km, Cl=Cl , f b i l e=f b i l e , f bac t=fbact , Qegg=Qegg , Qmilk=Qmilk )
M <= output$M
C <= output$C
#Write to r e s u l t s f o r t A
i f ( chem f ix & any( t [ i ]==round( t A*3600) ) ) {
XV
r e s u l t s [ , paste ( ” blood t ” , t [ i ] /3600 , sep=”” ) ] <= C[ physnames==”ven” ] * MW
#r e s u l t s [ , p a s t e (” f a t t ” , t [ i ] /3600 , sep =””)] <= C[ physnames==”adipose ” ]* MW
#r e s u l t s [ , p a s t e (” mamgland t ” , t [ i ] /3600 , sep =””)] <= C[ physnames==”mamgland ” ]* MW
r e s u l t s [ , paste ( ” l i v e r t ” , t [ i ] /3600 , sep=”” ) ] <= C[ physnames==” l i v e r ” ] * MW
r e s u l t s [ , paste ( ” kidney t ” , t [ i ] /3600 , sep=”” ) ] <= C[ physnames==” kidney ” ] * MW
r e s u l t s [ , paste ( ” muscle t ” , t [ i ] /3600 , sep=”” ) ] <= C[ physnames==” muscle ” ] * MW
r e s u l t s [ , paste ( ” heart t ” , t [ i ] /3600 , sep=”” ) ] <= C[ physnames==” heart ” ] * MW
r e s u l t s [ , paste ( ” bra in t ” , t [ i ] /3600 , sep=”” ) ] <= C[ physnames==” bra in ” ] * MW
#r e s u l t s [ , p a s t e (” carc ass t ” , t [ i ] /3600 , sep =””)] <= C[ physnames==”c arc ass ” ] * MW
#r e s u l t s [ , p a s t e (”abomasum t ” , t [ i ] /3600 , sep =””)] <= C[ physnames==”abomasum ”] * MW
#r e s u l t s [ , p a s t e (” i n t e s t i n e t ” , t [ i ] /3600 , sep =””)] <= C[ physnames==”i n t e s t i n e ” ] * MW
r e s u l t s [ , paste ( ” lung t ” , t [ i ] /3600 , sep=”” ) ] <= C[ physnames==” lung ” ] * MW
#r e s u l t s [ , p a s t e (” reprod t ” , t [ i ] /3600 , sep =””)] <= C[ physnames==”reprod ” ] * MW
#r e s u l t s [ , p a s t e (” egg t ” , t [ i ] /3600 , sep =””)] <= M[ physnames==”egg ” ] * MW #mg
#r e s u l t s [ , p a s t e (” mi lk t ” , t [ i ] /3600 , sep =””)] <= M[ physnames==”milk ” ] * MW #mg
} else i f ( ! chem f ix ) {
r e s u l t s [ , ”tmax” ] <= i f e l s e (C[ physnames==”ven”]> r e s u l t s [ , ”Cmax” ] , t [ i ] /3600 , r e s u l t s [ , ”tmax” ] )
r e s u l t s [ , ”Cmax” ] <= i f e l s e (C[ physnames==”ven”]> r e s u l t s [ , ”Cmax” ] ,C[ physnames==”ven” ] , r e s u l t s [ , ”Cmax” ] )
r e s u l t s [ , ”AUC 24h” ] <= r e s u l t s [ , ”AUC 24h” ] + C[ physnames==”ven” ]
}
}






Table B.1: Results of the measured concentrations by Lespine et al. (2005) and the model predicted
concentrations for Ivermectin. ND = non-detected.

































































































Table B.2: Results of the measured concentrations by Etuk & Onyeyili (2005) and the model predicted
concentrations for Chloramphenicol.

























































































































Table B.3: Results of the measured concentrations by Fernandez-Varon et al. (2006) and the model predicted
concentrations for Moxifloxacin.


























(b) Moxifloxacin concentrations in milk.
Hours after
exposure
Measured
value
(µg/mL)
Predicted
value
(µg/mL)
2 3.59 22.2
4 2.27 21.0
6 0.919 18.7
8 0.421 16.8
10 0.182 15.0
24 0.030 9.92
32 0.015 5.34
48 2.83
72 0.98
XX
